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ABSTRACT 
 
 
Does calcitriol play any role in regulating mineral metabolism or skeletal development in 
utero? Studies of Boston and Leuven vitamin D receptor (VDR) ablation models reported 
that Vdr null fetuses have normal serum minerals, parathyroid hormone (PTH), skeletal 
morphology and mineralization. However, Vdr null fetuses also have increased serum 
calcitriol, placental calcium transport, and placental expression of Pthrp and Trpv6. In the 
present study, we examined Cyp27b1 null fetal mice, which do not make calcitriol, to 
determine if loss of calcitriol has the same consequences as loss of VDR. Cyp27b1 null 
and WT females were mated to Cyp27b1+/- males, which generated Cyp27b1 null and 
Cyp27b1+/- fetuses from Cyp27b1 null mothers, and Cyp27b1+/- and WT fetuses from WT 
mothers. We confirmed that calcitriol was undetectable in Cyp27b1 null fetuses; 
therefore, they truly lacked calcitriol and were a useful model to address the research 
question. Cyp27b1 null fetuses had normal serum calcium, serum phosphorus, PTH, 
skeletal ash weight, ash mineral content, tibial length and morphology. Placental calcium 
transport was normal in Cyp27b1 null fetuses, while qPCR of placental mRNA confirmed 
loss of Cyp27b1 expression but no change in expression of key genes involved in 
placental mineral transport, including transient receptor potential cation channel 
subfamily V member 6 (Trpv6) and parathyroid hormone related protein (Pthrp). In 
summary, loss of calcitriol in Cyp27b1 null fetuses borne of Cyp27b1 null mothers did 
not significantly alter any measured parameter of mineral or bone homeostasis. 
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I. INTRODUCTION 
 
1.0 Preamble  
 
The following thesis involves the study of fetal mice which are unable to synthesize 
calcitriol. In order to understand and place this thesis in context, I will begin with a 
background review of bone and mineral metabolism. This will be followed by a 
discussion of how fetal bone and mineral metabolism differs from that of the adult, as 
well as what is currently known about the role of calcitriol from studies of human and 
animal models.  
 
Throughout this thesis the term phosphorus is used for consistency and simplicity, and 
because that is what is measured. It is acknowledged that in serum phosphorus 
predominantly exists as inorganic phosphates (dihydrogen and monohydrogen 
phosphate), while in bone it is largely in the form of hydroxyapatite, and in soft tissues 
and extracellular fluid (ECF) there are an abundance of organic phosphates complexed 
with carbohydrates, lipids, and proteins. 
 
There are many references to genes and proteins throughout this thesis. Please note that 
the following nomenclature is used throughout this thesis: human genes are written in 
uppercase font, genes in reference to animal models are written in italics and proteins are 
written in font matching the standard text. In cases where both human and animal models 
are being referenced, genes are referenced using the human nomenclature.  
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1.1 Adult calcium and bone homeostasis   
1.1.1 Structure and function of bone  
Although often misconceived as an inert structure, the skeleton is actually one of the 
body’s most metabolically active organs. As the largest organ of the human body, the 
skeleton makes up 15 % of the body’s weight, and comprises the highly specialized 
internal framework of the body. Beyond providing the internal structure of the body, the 
skeleton plays a critical role in the protection of internal organs, providing an attachment 
for muscle, and hosting hematopoiesis of bone marrow.1 Furthermore, bone is key player 
in mineral homeostasis, as it functions as a supply of mineral that can be rapidly 
mobilized. 
 
The bone is made up of two osseous tissues: cortical (compact) bone and trabecular 
(cancellous) bone. The cortical bone comprises the hard, outer layer of bone1 which forms 
a protective layer around the internal bone cavity. Cortical bone makes up nearly 80% of 
skeletal mass and is critical in providing structural support and weight bearing ability 
because of its high resistance to bending and torsion.1 By contrast, trabecular bone 
contributes approximately 20% of the skeleton and is largely found at the ends of long 
bones, as well as in the pelvis, skull, ribs and vertebrae.1 Trabecular bone is comprised of 
a meshwork of rigid trabeculae, thereby reducing skeletal weight without compromising 
bone strength. As the bone remodeling process begins at the bone surface, trabecular 
bone is more metabolically active than cortical bone, but also more vulnerable to 
damage when net bone loss occurs.1 
 3 
 
Figure 1: Cortical and Trabecular Bone.  Cortical bone comprises the hard, outer layer 
of bone which forms a protective layer around the internal bone cavity. Trabecular bone 
comprised of a meshwork of rigid trabeculae, thereby reducing skeletal weight without 
compromising bone strength. Used with permission from Dove Medical Press © 2015 
(Appendix A). 
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Unlike most other connective tissue matrices, bone is highly mineralized and has the 
unique ability to constantly regenerate itself through the process of bone turnover.2 There 
are three cell types in bone: the bone-forming osteoblasts, which when embedded in the 
mineral matrix become osteocytes, and the osteoclasts which are the bone resorbing 
cells.2  
 
1.1.1.1 Osteoblasts 
 
Osteoblasts are mononucleated cells that originate from mesenchymal stem cells (MSCs), 
and compromise 4-5 % of total cells in bone.3 Osteoblasts are critical in the creation and 
maintenance of the skeletal architecture, responsible for deposition of bone matrix and for 
osteoclast regulation. Osteoblasts initiate the process of bone formation by secreting 
osteoid, the unmineralized part of bone matrix that forms prior to maturation of bone 
tissue.1 Osteoblasts then deposit mineral, in the form of calcium, into the osteoid to 
mineralize the bone. As bone mineralizes, some osteoblasts become trapped within the 
matrix, becoming osteocytes.  
 
1.1.1.2 Osteocytes 
 
Some osteoblasts mature into osteocytes, which have deposited a mineralized matrix 
surrounding themselves, as opposed to remaining on the bone surface as functional 
osteoblasts.1  Osteoblasts mature into osteocytes through a process called 
osteocytogenesis, which involves a number of key osteogenic markers including osterix, 
bone sialoprotein, alkaline phosphatase, and steocalcin.4 In the adult skeleton, osteocytes 
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comprise 90-95% of all of the bone cells.4 These cells are evenly dispersed throughout the 
mineralized matrix and produce a dense network by connecting each other via gap 
junctions on their dendritic processes.4 Although historically osteocytes were believed to 
be passive cells, they are more recently understood to play a critical role in the normal 
function of the skeleton,3,5 particularly in targeted bone remodelling. Osteocytes are able 
to inhibit bone formation by way of sclerostin production. Conversely, when sclerostin 
production is inhibited, there is stimulation of bone formation.  Furthermore, osteocytes 
express osteoclast specific genes and proteins which allow them to demineralize their 
surroundings, through an active process called osteocytic osteolysis.  Later osteocytes act 
like osteoblasts again to restore mineral to their surroundings. 6-8  
1.1.1.3 Osteoclasts 
 
Normal physical activity can cause wear and microcracks within the bone known as 
microdamage. Bone remodelling, the process by which mature bone tissue is removed 
from the skeleton and new bone tissue is formed, is very important in the maintenance of 
the skeleton’s strength and ability to repair microdamage. This process is also important 
for the maintenance of blood mineral and alkali concentrations. In fact, when dietary 
absorption mineral is insufficient, the bone remodelling process accelerates in order to try 
to maintain sufficient mineral in the circulation.  Osteoclasts are largely responsible for 
the bone resorption process. Osteoclasts are large, multinucleated cells which belong to 
the monocyte-macrophage family. These cells make up only 1-2 % of bone cells and 
primarily function to resorb the bone matrix.9 Osteoclasts produce a number of enzymes, 
chiefly alkaline phosphatase, as well as acid, which break down collagen, calcium and 
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phosphorus in the bone. First, mineralized bone is broken down into fragments, then the 
osteoclasts engulf the fragments and digests them within cytoplasmic vacuoles. Calcium 
and phosphorus released from the bone during osteoclastic resorption of the bone are then 
released into the bloodstream to meet the body’s physiological requirements.  
1.1.2 Serum minerals  
1.1.2.1 Calcium  
 
Calcium is the most abundant mineral in the human body, with approximately 1000 g of 
calcium present in the adult. Nearly all of the body’s calcium (99 %) exists in the skeleton 
as hydroxyapatite crystal [(Ca10(PO4)6(OH)2],
10 which provides skeletal strength and 
provides a dynamic store to maintain intra- and extracellular calcium concentrations. The 
remaining 1 % of calcium can be found in the blood, ECF and soft tissues. Of the blood 
total calcium, 50 % is ionized (biologically active), 40 % is bound to albumin, and 10 % 
exists as a complex with either citrate (C6H5O7
3-) or phosphate (PO4
-) ions.11 As ionized 
calcium is the biologically active form, it can be used as a more precise measure of 
calcium normality.  A G-protein coupled receptor, called the calcium sensing receptor 
(CaSR), plays a critical role in calcium homeostasis through its ability to sense free 
ionized calcium.2 The CaSR is the principal mechanism for sensing calcium in the 
parathyroid cells, C cells, and several nephrons in the kidney, as well as in the bone and 
intestine.12  
 
 
 7 
1.1.2.2 Phosphorus  
 
Phosphorus is the second most abundant essential mineral in human body after calcium. It 
not only plays a role in numerous biologic processes, including energy metabolism and 
bone mineralization, but also provides the structural framework for deoxyribonucleic 
(DNA) and ribonucleic acid (RNA). A large portion of phosphorus in the body (80-90 %) 
exists in bone and teeth in the form of hydroxyapatite crystal, with the remainder 
distributed in soft tissues and ECF.13 There are two forms of phosphorus in the ECF: 
organic phospholipids which are a major component of cell membranes, and inorganic 
phosphate, which is required for cellular function and skeletal mineralization.14 It is 
believed that there is a phosphorus sensor, which acts analogous to the CaSR to regulate 
serum phosphorus, however, the mechanism by which phosphorus is sensed is currently 
unknown.  
1.1.3 Calciotropic and phosphotropic hormones  
 
Normal calcium and bone homeostasis in the adult can almost entirely be explained by 
the interactions of several regulatory hormones, including parathyroid hormone (PTH), 
fibroblast growth factor-23 (FGF23), calcitriol, PTHrP, and the sex steroids (estradiol and 
testosterone). Loss of any one of these hormones can have significant consequences for 
the adult.  
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1.1.3.1 PTH  
 
 PTH is produced by the chief cells of the parathyroid glands as a pre-pro-peptide 
consisting of 115 amino acids. Following removal of the 25 amino acid pre-sequence and 
the 6 amino acid pro-sequence, the mature PTH peptide, 84 amino acids in length, is 
secreted.15 PTH is secreted in response to small decreases in blood ionized calcium levels, 
or increased phosphorus levels, in order to maintain calcium and phosphorus homeostasis 
in the blood. PTH aids in calcium homeostasis by promoting resorption of bone and 
thereby release of skeletal calcium, acting on the kidneys to reabsorb calcium, increasing 
renal phosphorus excretion, and enhancing intestinal calcium absorption by stimulating 
Cyp27b1, which encodes 1-alphahydroxylase (1αOHase), the enzyme necessary for the 
final hydroxylation step to form active calcitriol. High blood ionized calcium and 
calcitriol inhibit PTH release, while high serum phosphorus stimulates PTH. PTH is also 
regulated by FGF23, which promotes excretion of phosphorus into the urine, and also 
reduces circulating calcitriol levels, thereby decreasing intestinal calcium and phosphorus 
absorption.16  
 
Blood ionized calcium levels are sensed within a tight range by the CaSR on the surface 
of the parathyroid cell, which is abundantly produced by the plasma membrane of these 
cells.16 The CaSR becomes activated upon binding to calcium, which leads to inhibition 
of PTH synthesis and release.16 PTH binds to Parathyroid Hormone Recepor Type 1 
(PTH1R) on the osteoblast surface, thereby stimulating osteoblast activity in order to 
produce bone matrix.   
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Prolonged or higher amplitude stimulation by PTH causes a downregulation in 
osteoblastic bone-forming activity, and instead, triggers osteoblasts to produce Receptor 
Activator of Nuclear Factor kappa-B Ligand (RANKL). In turn, RANKL stimulates 
osteoclast formation, recruitment and activity.16 In this way, PTH couples osteoblast and 
osteoclast activity determining which process will predominate.  
 
1.1.3.2 FGF23 
 
FGF23 is a hormone produced by osteocytes and osteoblasts, which acts on distant tissues 
to regulate the supply of phosphorus at the bone surface.17 Study of disorders of 
phosphorus homeostasis has demonstrated that FGF23 plays a critical role in regulation of 
renal phosphorus and vitamin D metabolism. FGF23 has overlapping function with PTH 
to reduce phosphorus reabsorption in the kidneys; however, it has opposing effects on 
calcitriol homeostasis.  
 
FGF23 acts on two main transport proteins within kidney tubules, sodium-phosphate 
transporters NaPi2a and NaPi2c, in order to regulate renal phosphorus. Napi2a and 
Napi2c are expressed in the apical membrane of the proximal tubule where they are 
responsible for regulating renal phosphorus reabsorption. FGF23 downregulates Napi2a 
and Napi2c, thereby leading to increase renal phosphorus excretion.18 
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FGF23 acts to reduce calcitriol through two ways. The first is through a reduction in  
renal expression and activity of 1αOHase, also known as Cytochrome P450 family 27 
subfamily B member 1(Cyp27b1), which synthesizes calcitriol by hydroxylating 
25OHD.19 The second is through increased expression and activity of 24-hydroxylase 
(24OHase), through Cytochrome P450 family 24 subfamily A member 1 (Cyp24a1), 
which catabolizes calcitriol and 25OHD by adding a hydroxyl group in the 24 position.19 
Through its ability to reduce serum calcitriol, FGF23 acts indirectly to reduce intestinal 
phosphorus absorption. FGF23 may also act directly to decrease intestinal phosphorus 
absorption through interaction with intestinal sodium-phosphate transport protein NaPi2b, 
located on the villi of the small intestine. By way of FGF23’s direct and indirect actions 
on intestinal phosphorus absorption, total serum phosphorus is reduced. In contrast, loss 
of FGF23 leads to hyperphosphatemia, due to loss of renal phosphorus excretion, as well 
as markedly high levels of calcitriol which lead to increased intestinal absorption of 
phosphorus.19  
 
FGF23 also acts on the parathyroid glands to inhibit PTH, which contributes to lowering 
serum calcitriol.20 High serum phosphorus and calcitriol are potent stimuli for FGF23 
synthesis and release, whereas PTH modestly stimulates FGF23.20 
 
1.1.3.3 Vitamin D production and metabolism  
 
Calcitriol is the active, or hormonal, form of vitamin D, and plays numerous biologically 
important roles. Vitamin D is either formed in the skin from 7-dehydrocholesterol (7-
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DHC) in response to UV exposure, or ingested through the diet from both food and 
supplements in the form of Vitamin D3.
21 The conversion from biologically inactive 
Vitamin D3 to the active form calcitriol requires two hydroxylation reactions (Figure 1). 
Vitamin D3 is preferentially removed from the skin and transported into the circulation by 
the vitamin D binding protein (DBP).21 DBP shuttles vitamin D to fat and muscle for 
storage and to the liver, where the first hydroxylation reaction occurs.  Here vitamin D is 
metabolized to 25-hydroxyvitamin D (25OHD) via hepatic 25-hydroxylase (25OHase). 
DBP then transports 25OHD to the kidney where renal 1αOHase facilitates its conversion 
to 1,25-dihydroxyvitamin D (calcitriol). The production of calcitriol in the kidney is 
tightly controlled, being stimulated by PTH and inhibited by calcium, phosphate and 
FGF23. Furthermore, calcitriol is able to feedback to inhibit its formation and enhance its 
catabolism.21  
 
The availiablilty of substrate, amount of enzyme, cofactor availability and enzymatic 
activity of Cyp24a1 all play a role in the regulation of calcitriol through 1αOHase. 
Cyp24a1 encodes for the enzyme 24OHase which hydroxylates calcitriol into 1,24,25-
trihyroxyvitamin D (calcitroic acid) and 1,24,25-dihydroxy-26,23-lactone, which are 
thought to be inactive, and can be excreted from the body through bile and urine.21 
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Figure 2: Vitamin D Production and Conversion into Calcitriol. Vitamin D is 
produced in the skin via UV exposure and ingested through the diet via food and 
supplements. The conversion from biologically inactive vitamin D3 to calcitriol requires 
two hydroxylation reactions; the first in the liver by 25OHase and the second in the 
kidney by 1αOHase.  
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1.1.3.3.1 Calcitriol  
 
Calcitriol plays an important role in both the child and adult by increasing blood calcium 
and phosphorus levels. It increases the absorption of both in the intestines, increasing 
reabsorption of both by the kidneys, and aiding in the release of calcium and phosphorus 
from bone (Figure 2). Calcitriol may also play a role beyond bone and mineral 
homeostasis, as observational studies support an association between vitamin D and 
cardiovascular, immune, musculoskeletal and metabolic disorders.22 The focus of my 
thesis is on the role of calcitriol in fetal bone and mineral homeostasis.  
 
Studies of mice which lack the vitamin D receptor (Vdr null) have demonstrated that 
calcitriol’s main action is to increase intestinal absorption of calcium and phosphorus.23,24 
When the demand for calcium increases, such as during growth, pregnancy, or lactation, 
increased synthesis of calcitriol in turn increases the efficiency of intestinal calcium 
absorption.21 Calcium is absorbed in the intestines by an energy-dependent, transcellular 
(active) pathway, and also a paracellular (passive) pathway through tight-junctions 
(Figure 3).25 Calcitriol is the main stimulator of active intestinal calcium absorption 
through genomic actions. Calcium enters intestinal cells through the apical calcium 
channel, transient receptor potential vanilloid type 6 (TRPV6),26 and is translocated 
through the interior of the enterocyte, likely carried by calcium binding protein 
Calbindin-D9k (S100G).
26 Calcium is then pumped out of the basal membrane of the cell 
via the intestinal plasma membrane pump Ca2+-ATPase (Figure 3). There is increasing 
evidence to also suggest that calcitriol can also enhance passive intestinal calcium 
absorption by regulating tight junction proteins.27 
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The kidneys also play an important role in calcium homeostasis. When there is a drop in 
calcium levels in the blood, PTH acts on the kidneys to retain calcium and excrete 
phosphorus.16,28 When PTH is bound to PTH1R, there is increased activity of 1αOHase 
leading to an increased calcitriol synthesis. In turn, the increase in calcitriol stimulates 
intestinal calcium absorption to increase calcium levels in the blood stream.  
The skeleton serves as major supply of calcium and phosphorus when intestinal 
absorption and renal handling are not enough to maintain normal mineral levels within 
the blood. There is some amount of calcium and phosphorus that are readily available to 
be mobilized from bone, but these stores are rapidly depleted. When greater or prolonged 
release of calcium from the bone is required, osteoclastic resorption must be activated in 
order to supply the blood with the mineral it needs. In periods of even greater demand for 
calcium, osteocytic osteolysis is also activated. 
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Figure 3: Classical actions of calcitriol.21 Calcitriol interacts with PTH and FGF23 to 
regulate calcium and phosphorus homeostasis. Production of calcitriol is stimulated by 
PTH and inhibited by FGF23 in the kidney. In turn, calcitriol acts to inhibit PTH 
synthesis and stimulate FGF23. Used with permission from John Wiley & Sons, INC,  
© 2013 (Appendix B). 
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Figure 4: Active and passive intestinal calcium absorption.  Calcium enters the 
intestine through the apical calcium channel, TRPV6, is translocated through the interior 
of the enterocyte, which is thought to occur with help of the calcium binding protein 
Calbindin-D9k. Calcium is then pumped out of the basal membrane of the cell via the 
intestinal plasma membrane pump Ca2+-ATPase. Reprinted by permission from 
MacMillan Publishers Limited ©2014 (Appendix C). 
 
 
 
 
 
 
 
 
\ 
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1.1.3.3.2 Vitamin D receptor  
 
Calcitriol is transported to target cells where it diffuses into the cytoplasm and binds to 
the VDR. VDR possesses a nuclear localization signal (NLS) and may enter the nucleus 
bound to calcitriol; alternatively, calcitriol may diffuse into the nucleus and bind to the 
unbound VDR that has translocated to the nucleus.29 Calcitriol binds stereospecifically to 
the VDR causing a conformational change into a transcriptionally active form.  Once 
transcriptionally active, VDR is able to form a heterodimer with the 9-cis-retenoic acid 
receptor (RXR).29 The VDR/RXR heterodimer recognizes a specific DNA sequence or 
vitamin D response element (VDRE) made up of two hexameric nucleotide half-sites 
separated by three base-pairs (Figure 4).30 These actions trigger the expression of 
networks of target genes whose functions combine to cause tissue-specific biological 
responses including: complex actions required for mineral homeostasis and control of 
growth, differentiation and activity of numerous cell types including those of the immune 
system, skin, the pancreas and bone as well as many other targets.31 
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Figure 5: VDR gene structure and regulation of vitamin D dependant target genes. 
Calcitriol binds stereospecifically to the VDR causing a conformational change into a 
transcriptionally active form.  Once transcriptionally active, VDR forms a heterodimer 
with RXR. The VDR/RXR heterodimer recognizes a specific DNA sequence, VDRE, 
which triggers the expression of networks of target genes whose functions combine to 
cause tissue-specific biological responses. 
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1.1.4 PTHrP 
In the early 1940’s, studies of humoral hypercalcemia of malignancy (HHM), 
characterized by an abnormal elevation of serum calcium associated with malignant 
tumors, theorized a “PTH-like” hormone.32 Subsequent studies led to the biochemical 
characterization of HHM and the identification and characterization of PTHrP.33,34 Both 
PTHrP and PTH genes share high sequence homology at the amino-terminal portion, such 
that the genes share 8 of the first 13 amino acids and predicted secondary structure of the 
subsequent 21 amino acids.34-36 These similarities allow both peptides to bind and activate 
the same receptor, PTH1R.37  
 
In the adult, PTHrP is typically absent from the circulation with exception to a gradual 
increase during pregnancy, coming from the placenta and the breasts, and a more 
pronounced increase during lactation. Although PTHrP doesn’t normally have an 
endocrine function, it may have an autocrine, paracrine or intracrine function in tissues 
where it is locally produced.38 
 
As PTHrP is expressed in almost all tissues, it serves a variety of functions in the body, 
including in the skeleton, the cardiovascular system, the placenta and the breast. In the 
skeleton, PTHrP helps to synchronize chondrocyte differentiation in the growth plates of 
long bones, stimulating growth.39,40 Within the cardiovascular system, PTHrP is induced 
by vasoconstrictive agents and acts as a vasodilator in resistance vessels, suggesting that 
it may act as a local modifier of blood flow.41 Perhaps the most well-known functions of 
PTHrP are within the placenta and the breast. During pregnancy, PTHrP is critical in 
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active transport of calcium from the mother to the fetus.42 PTHrP remains critical into 
lactation where it is involved in the regulation of calcium metabolism and has been found 
to be highly expressed in the milk.43,44  
1.1.5 Gonadal steroid hormones 
Sex is an important determining factor in the size and shape of the skeleton, with the 
differences in skeletal shape between sexes reflecting the need of the female skeleton to 
accommodate gestation and delivery of offspring. Estradiol is essential for the bone 
changes that occur during puberty in both males and females. Females lacking aromatase, 
an enzyme in the steroid synthesis pathway necessary for synthesis of estradiol, and males 
lacking the estrogen receptor,  do not undergo a growth spurt and do not experience 
epiphyseal closure.45 During adulthood estradiol, and indirectly testosterone through 
conversion to estradiol, influences the growth and maintenance of the skeleton. 
Throughout all stages of life bone is periodically resorbed and replaced with new bone. 
Deficiency of estradiol causes bone loss that is associated with an unbalanced increase in 
the number and activity of osteoclasts and osteoblasts.46 Conversely, sufficiency of 
estradiol also acts to decrease bone resorption and maintain a balance between bone 
resorption and formation processes. As a result of the aging process, both men and 
women lose bone and are prone to osteoporosis in later years. Women are more likely to 
develop osteoporosis as they gain less bone during puberty and experience an abrupt loss 
of estrogens during menopause.45   
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1.1.6 Role of the intestines  
Although bone resorption can maintain serum mineral within the normal range, the only 
way that mineral stores in the bone can be replenished is through dietary intake. Once 
ingested, calcium and phosphorus are almost exclusively absorbed in the small intestine.  
Most of the active transport of calcium occurs in the duodenum and upper jejunum of the 
small intestine, while passive transport of calcium, and both active and passive absorption 
of phosphorus, can occur throughout the entire intestine.  
 
Calcium is absorbed through the intestinal epithelium through one of two routes: 1) 
between the cells (paracellular pathway) or 2) through the cell (transcellular pathway). 
When calcium concentrations within the lumen are high, the passive paracellular pathway 
is the prominent route of absorption. The paracellular pathway is driven by the 
electrochemical gradient of the lumen and the integrity of intracellular tight junctions.47 
During vitamin D deficiency, excess intake of dietary calcium can increase serum 
calcium concentrations through this pathway. The active transcellular pathway is 
regulated by calcitriol and is the less predominant pathway as the concentration of 
calcium is usually higher in the lumen than inside the cell. The transcellular pathway 
involves entry of calcium via the apical calcium channel TRPV6, transport of calcium 
through the cell by calbindin-D9k and extrusion of calcium through the basolateral 
membrane by Ca2+ATPase (Pmca1).27  
 
Phosphorus can also be absorbed through paracellular and transcellular pathways. Like 
paracellular absorption of calcium, paracellular phosphorus absorption is dependent on 
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the luminal electrochemical gradient and integrity of tight junctions. On the other hand, 
the transcellular phosphorus transport mechanism differs from that of transcellular 
calcium transport. Phosphorus is actively transported through the intestine via the sodium 
phosphate transporter NaPi2b, which is regulated by calcitriol,  phosphorus intake and 
FGF23.48  
1.1.7 Role of the kidneys  
In the human adult, the kidney filters about 10 g of calcium per day. However, only 100-
200 mg of this amount is excreted in the urine, meaning that approximately 98-99 % of 
the filtered calcium is reabsorbed into the circulation.49 The majority of filtered calcium is 
reabsorbed in the proximal tubule, while 20 % is reabsorbed in the loop of Henle, 10 % 
by the distal convoluted tubule and 5 % by the collecting duct (Figure 5).49 Much like 
intestinal calcium absorption, renal reabsorption of calcium can occur through either 
paracellular or transcellular pathways. Paracellular renal calcium transport makes up the 
majority of calcium transport within the kidney.50 The mechanism of the active, 
transcellular pathway is proposed to be the same as the transcellular pathway in the 
intestine. Calcium enters the tubule via the apical calcium channel TRPV6,  calcium is 
transported through the cell by calbindin-D9k and calcium is secreted through the 
basolateral membrane by Ca2+ATPase (Figure 6).50 
 
Calcium handling in the kidney is regulated by a number of calciotropic hormones. The 
glomerular filtration rate and calcium reabsorption are increased by the actions of PTH 
and PTHrP.10 PTH stimulates Cyp27b1 in order to hydroxylate 25OHD to become 
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calcitriol. In turn, the produced calcitriol acts on the intestines to increase intestinal 
calcium absorption. Calcitriol, estradiol and calcium intake also play a role in renal 
handling of calcium by modulating the transcription of calcium transporters TRPV5 and 
TRPV6.51 
 
The kidneys also play a role in the regulation of phosphorus homeostasis. Maintenance of 
serum phosphorus levels is principally achieved by regulation of inorganic phosphate (Pi) 
reabsorption within the glomerular filtrate. A large portion of phosphorus absorption 
(approximately 85%) occurs in the proximal tubule. Within the tubule Pi transport is an 
energy dependent process that requires sodium.49 Sodium phosphate transporters, NaPi2a 
and NaPi2c, are located on the apical brush border membrane of cells of the renal 
proximal tubule, using energy created from sodium movement down its gradient, to move 
Pi from the filtrate into the cell.52 Phosphorus transport in the kidney is regulated by PTH, 
calcitriol and FGF23. Calcitriol acts to stimulate phosphorus reabsorption, while PTH and 
FGF23 inhibit phosphorus absorption in the renal proximal tubule and reduce the activity 
of NaPi2a and NaPi2c. 
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Figure 6: Renal calcium reabsorption. Calcium is filtered at the glomerulus, with the 
ultrafilterable portion of plasma calcium entering the proximal tubule. Within the 
proximal convoluted tubule, 60-70 % of filtered calcium is reabsorbed, while 10 % is 
reabsorbed in the distal convoluted tubule. The hoop of Henle reabsorbs about 20 %, with 
another 5 % of filtered calcium reabsorbed in the collecting duct. Adapted from the 
American Society of Nephrology © 2014 49(Appendix D).   
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Figure 7: Renal transcellular calcium transport.53 Calcium enters the tubule via the 
apical calcium channel TRPV6, calcium is transported through the cell by calbindin-D9k 
and calcium is secreted through the basolateral membrane by PMCA1b (Ca2+ ATPase). 
Used with permission from Springer Nature © 2005 (Appendix E).  
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1.1.8 Role of the skeleton  
Bone undergoes remodelling continuously due to the actions of osteoblasts and 
osteoclasts to build and breakdown bone respectively. During childhood, there is a 
positive bone balance, with more bone formation than resorption, in order to allow for 
bone growth and development. By adulthood, bone balance reaches equilibrium that is 
maintained through the reproductive years. However, bone resorption exceeds bone 
formation after menopause and in the elderly, causing a negative bone balance, which 
may lead to osteoporosis.  
 
Regulation of bone remodelling occurs both locally and systemically. As previously 
mentioned, PTH is a key systemic regulator of bone remodelling. With physiological 
pulses of PTH, or pharmacological administration of short-acting PTH analogs such as 
teriperatide (FORTEO®), osteoblasts are stimulated causing net bone formation. In 
contrast, during periods of prolonged stimulation, such as during hyperparathyroidism, 
this leads to stimulation of net bone resorption. 54 Calcitriol regulates bone remodelling 
indirectly by stimulating intestinal calcium absorption, as calcium is a growth factor for 
osteoblasts. Furthermore, high levels of calcitriol lead to an increase in osteoclast activity, 
likely through the RANKL pathway.55 
 
1.2 Human conditions of altered vitamin D metabolism  
1.2.1 Nutritional vitamin D deficiency  
Vitamin D deficiency is a global issue ranging from severe to moderate.56-58  Severe 
deficiency is characterized by 25OHD levels less than 50 nmol/L (10-12 ng/mL), while 
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moderate vitamin D insufficiency is characterized by levels of 25OHD between            
50-75 nmol/L ( 20-30 ng/mL).56,59-62 Based on these criteria it has been estimated that 20-
100 % of the elderly population in Canada, the United States and Europe are vitamin D 
deficient.56,59,63-65 However, the elderly are not the only population at risk. Children and 
teenagers are also at high risk for vitamin D deficiency and insufficiency, through 
avoidance of sunlight and low intake of food sources that contain vitamin D.66,67   
 
Calcitriol is chiefly responsible for ensuring that sufficient mineral is absorbed by the 
intestines to allow for skeletal growth in the child and to maintain a neutral calcium 
balance in the adult. Therefore, a major result of vitamin D deficiency is a reduction in 
intestinal calcium absorption below the level that is required to meet the demands of a 
growing child’s skeleton.56,59 As a consequence, mineral homeostasis is disrupted with an 
initial drop in ionized calcium levels and a resultant secondary hyperparathyroidism.56,59 
If the deficiency is not severe, it is possible for the elevated PTH levels to increase 
1αOHase activity enough to raise calcitriol levels and increase intestinal calcium 
absorption to achieve normocalcemia. However, if the deficiency worsens or persists, 
calcitriol levels fall and hypocalcemia, hypophosphatemia and rickets ensue. This 
hypophosphatemia occurs in part due to reduced intestinal absorption, but is likely mainly 
due to secondary hyperparathyroidism which causes renal phosphate wasting.65,68  
1.2.2 Pseudovitamin D deficiency  
 
Pseudovitamin D deficiency  (PDDR) is an autosomal recessive disorder caused by an 
inactivating mutation of the Cyp27b1 gene which encodes 1αOHase, responsible from the 
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conversion of 25OHD into calcitriol.69 Patients with PDDR are clinically normal at birth 
and most often come to medical attention at 1–2 years of age with poor growth, poor 
gross motor development, and generalized muscle weakness.70 Serum chemistries in 
patients with PDDR are similar to, but can be more severe than, patients with nutritional 
vitamin D deficiency, including: hypocalcemia, hypophosphatemia and secondary 
hyperparathyroidism. Unlike nutritional vitamin D deficiency, serum calcitriol 
concentrations are usually low, however, 25OHD concentrations tend to be normal.70  
Treatment of PDDR requires physiological doses of calcitriol or 1-alpha-hydroxyvitamin 
D which can undergo a hydroxylation reaction in the liver to become calcitriol. 
 
1.2.3 Hereditary vitamin D resistant rickets 
 
Hereditary vitamin D resistant  rickets (HVDRR) is a rare, autosomal recessive form of 
rickets characterized by resistance to calcitriol caused by a defect in the VDR gene.71 
Mutations in the VDR gene have been identified at both the calcitriol-binding and DNA-
binding domains. Thus, there is a spectrum of HVDDR severity ranging from impaired 
binding or impaired signalling to complete absence of functional receptors. Patients with 
HVDRR appear normal at birth and begin to present with symptoms of calcitriol 
deficiency within the first 2-8 months of life, including onset of rickets, hypocalcemia, 
hypophosphatemia, secondary hyperparathyroidism and very high circulating 
concentrations of calcitriol.72 Additionally,  some patients with HVDRR develop alopecia 
which may be total or incomplete between ages 2 and 12 months.72 Treatment 
effectiveness is dependent on the degree of hypocalcemia. If there is partial resistance to 
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calcitriol, treatment with pharmacologic doses of calcitriol can upregulate calcium 
absorption and heal the symptoms of rickets. However, if there is complete resistance to 
calcitriol, treatment with calcitriol is ineffective and infusion with calcium is necessary to 
compensate for intestinal mineral absorption.72 Treatment is generally unable to reverse 
alopecia, which suggests that the skin/follicle action of calcitriol or VDR is not related to 
calcium and/or phosphorus metabolism. Moreover, individuals with PDDR do not get 
alopecia, which suggests that alopecia is a function of VDR and not calcitriol, which 
implies that there is another ligand for VDR.72 
1.3 Animal models of altered vitamin D metabolism 
 
In order to better study disorders of vitamin D metabolism, numerous animal models have 
been established that either lack VDR or Cyp27b1. These models quite closely mimic the 
human counterparts of PDDR and HVDRR. 
1.3.1 Vdr null mice 
The Vdr knock out mouse model mimics HVDRR and has been used to study the 
pathophysiology of altered vitamin D metabolism. There are currently several different 
models of VDR knockout mice, which differ by removal of either the first or second zinc 
finger, responsible for DNA binding. All models of Vdr null mice are hypocalcemic, 
hypophosphatemic and a characterized by secondary hyperparathyroidism and a rachitic 
(rickets –like) phenotype.23,26 The rachitic phenotype of Vdr null mice is largely due to 
the indirect role of calcitriol on the skeleton through its actions to increase intestinal 
mineral absorption. In fact, Vdr null mice  can be genetically rescued (phenotypically 
normal) by selectively expressing VDR only within intestinal cells.73,74 On the other hand, 
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when VDR is ablated solely from intestinal cells or when calcium is restricted in the diet, 
the rachitic phenotype ensues.74 Moreover, loss of Vdr from chondrocytes, osteocytes or 
osteoblasts of bone does not produce a rachitic phenotype, confirming that the phenotype 
is specific to disruption of intestinal calcium absorption.74-76 
In order to allow for normal fertility and prevention of skeletal abnormalities, Vdr null 
mice are often kept on a “rescue diet” that is both high in calcium and phosphorus.77  This 
type of diet is used in almost all studies of Vdr ablated mice.78 Vdr null mice also 
experience alopecia which is unable to be cured with the rescue diet.77 With these 
phenotypic similarities between Vdr null fetuses and babies with HVDRR, it is clear that 
Vdr null mouse is an excellent model for human HVDRR.  
1.3.2 Cyp27b1 null pigs 
PDDR can be studied in the Hannover pig strain, which lack 1αOHase activity due to a 
naturally occurring null mutation in Cyp27b1.79 In this animal model, the disease is 
passed on in an autosomal recessive manner. During fetal development, Cyp27b1 null  
piglets are phenotypically normal with normal serum calcium, phosphorus and skeletal 
mineralization.80 By 4-6 weeks post birth, however, Cyp27b1 null piglets begin to display 
a rachitic phenotype with hypocalcemia, hypophosphatemia, and low to non-detectable 
levels of calcitriol. It is at this stage that the pigs closely resemble the human PDDR 
condition.  
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1.3.3 Cyp27b1 null mice 
A mouse model of PDDR has also been generated to better study the disease. Mice 
lacking 1αOHase activity were generated by knocking out exon 8 of the Cyp27b1 gene in 
order to generate a null allele.81 Like the Cyp27b1 null pigs, homozygous mutants are 
phenotypically normal at birth. However, full progression of PDDR symptoms occurs 
postnatally. By weaning (21 days post birth) hypocalcemia, hypophosphatemia, 
hyperparathyroidism and rickets are evident, and osteomalacia is present by early 
adulthood.82  
 
1.4 Fetal bone and mineral metabolism  
 
The fetal development period is unique in that it is a period of rapid development in 
which specific needs must be met by the developing fetus.  Within the fetal development 
period, the fetus must meet several goals, including transport of mineral across the 
placenta, maintaining appropriate mineral concentrations within the circulation and 
adequately mineralizing the skeleton before birth. 
 
Unlike in the adult, the intestines, kidneys and skeleton are not dominant sources of 
mineral during fetal development. Instead, the placenta must supply the fetal mineral 
requirements by actively transporting calcium, phosphorus, and magnesium from the 
maternal circulation.  
 
The fetus must also maintain the appropriate amount of mineral in the circulation 
necessary for normal function of the fetal system. Among mammalian species, including 
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rhesus monkeys,83,84 lambs,85-88 calves,87,89 rodents,87,90 and pigs,80,91,92 it has been 
consistently shown that fetal calcium concentrations are higher than that of the maternal 
values. The biological relevance of this increase in fetal calcium remains unknown. 
However, it appears to be independent of the maternal calcium level, as fetal calcium 
levels have been shown to be unaltered during maternal normocalcemic, hypocalcemic 
and hypercalcemic states.93  
 
Fetal phosphorus levels also tend to be higher than maternal values, with fetal values in 
rodents,94-98 lambs,88,99,100 pigs,80,91 calves,87 and foals87 observed to be 0.5-1.0 mM higher 
than maternal values. Just as fetal calcium levels are set independently of the mother, 
when mothers are hyperphosphatemic, fetal phosphorus values remain normal.101,102 
However, a few studies disagree. Studies of both pregnant rats and sheep indicate that 
maternal hyperphosphatemia leads to increased fetal phosphorus levels.103,104 
 
Fetal serum magnesium values also appear to be set independently of maternal values; 
however, the data are more variable with respect to whether they are above or below 
maternal levels. Moderate increases in serum magnesium are observed in fetal mice and 
foals,87,105,106while fetal rats have a moderate increase to no change.87,107 Both slight 
increases 88,108,109 and decreases 87,99 in serum magnesium have been observed in fetal 
lambs.  
 
The fetus must also be able to meet the mineral demand necessary to successfully 
mineralize the fetal skeleton before birth.  The majority of this mineralization process 
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occurs rapidly within the latter part of pregnancy. In humans, 20-30 g of calcium are 
necessary to mineralize the fetal skeleton, 80 % of which is accreted in the third 
trimester.110 Similarly, in rats 95 % of the 12.5 g of calcium necessary for mineralization 
is accreted during the last 5 days of the 21-day gestation period.111 These intervals 
correspond with increased rates of calcium absorption.  
1.4.1 Fetal bone development  
At the beginning of human fetal bone development, 8 weeks post-fertilization, the pattern 
of the skeleton has largely been determined. Ossification or mineralization is an important 
component of bone development and growth. Primary ossification centers form in the 
long bones and vertebrae between weeks 8 and 12 of embryo development. 112 There are 
two main ossification process that occur during fetal bone development: intramembranous 
and endochondral ossification. Intramembranous (also known as mesenchymal) 
ossification is the process in which mesenchymal cells in the embryonic or fibrous 
connective tissue become osteoblasts, in order to form the bone matrix. Conversely, 
endochondral ossification is the process by which cartilaginous scaffolds are created for 
most bones, which progressively lengthen and contribute to longitudinal growth, before 
being gradually replaced by bone.113 Osteoblast progenitors in the perichondrium 
differentiate into osteoblasts, and as primary ossification centers expand and secondary 
ossification centers form, this results in the formation of the epiphyseal growth plate 
(Figure 7).  
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Figure 8: Endochondral bone development in the fetus. The areas of the growth plate 
include the resting zone, proliferating zone, differentiating chondrocytes zone and a zone 
of hypertrophic chondrocytes. Blood vessels invade the hypertrophic area and osteoclasts 
resorb the ossified cartilaginous matrix and osteoblasts derived from the bone collar 
replace the matrix with bone. Adapted with permission from John Wiley & Sons Inc © 
2013. (Appendix F) 
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1.4.2 Calciotropic and phosphotropic hormones  
1.4.2.1 PTH 
 
PTH circulates at lower levels in the fetal circulation in comparison to maternal values in 
rodents, lambs, and calves.89,98,114-116 Intact PTH is not able cross the placenta from the 
mother to the fetus; consequently, PTH within the fetal circulation is of fetal origin. PTH 
synthesis and release in the fetal circulation is thought to be suppressed by the activation 
of the CaSR on the fetal parathyroids by the high levels of total and ionized calcium.90 
Furthermore, knockout of CaSR in fetal mice leads to increased PTH.117 Active placental 
transport of calcium may also contribute to the low levels of circulating fetal PTH by 
bringing calcium into the circulation through a route that does not require PTH.117 
Moreover, maternal hypercalcemia has been shown to increase the transfer of calcium to 
the fetus and further suppress the fetal PTH level, even if the fetal serum calcium does not 
change.90 Low circulating PTH is not exclusive to fetal animals. In fact, infants have low 
circulating PTH in comparison to maternal and adult values, with concentrations as low 
as <0.5 picomolar (pM) observed.118 This suppression of fetal PTH is apparent as early as 
19 weeks of gestation.119  
In mice, absence of fetal PTH causes fetal hypocalcemia, hypophosphatemia, low 
amniotic fluid mineral content, and reduced skeletal mineral content.98 This suggests that, 
despite its low circulating levels, PTH is still required to achieve normal mineralization of 
the skeleton prior to birth. Despite reduced skeletal mineral content, endochondral bone 
development is normal, suggesting that the role of PTH in bone homeostasis is through its 
ability to maintain serum calcium concentration and not through osteoblast physiology.  
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1.4.2.2 PTHrP 
 
Prior to the discovery of PTHrP, studies noted that infants have an increased PTH-like 
bioactivity and low or undetectable amounts of immunoreactive PTH in the cord blood in 
comparison to maternal values.118,120It was hypothesized that fetal blood contained a 
PTH-like factor that was contributing to the increased PTH-like bioactivity, which was 
later confirmed by the discovery of PTHrP. Human fetuses were found to have up to a 
fifteen-fold greater amount of PTHrP than PTH in the circulation.121 This phenomenon 
was also confirmed in studies of fetal pigs122 and sheep.123  
 
Most of what is known about the role of PTHrP in fetal bone metabolism comes from the 
study of Pthrp null fetal mice. These mice display hypocalcemia, hypophosphatemia, and 
increased PTH.124,125 Furthermore, Pthrp null fetal mice have abnormal skeletal features 
including: shortened limbs, domed skulls, shortened mandibles and accelerated 
mineralization of bone.126 The increase in PTH suggests that it increases to compensate 
for lack of PTHrP; however, compensation was not achieved because hypocalcemia 
ensued. Pth null fetuses and other fetuses that lack their parathyroid glands (Hoxa3 nulls 
and Gcm2 nulls)98 do not have a compensatory increase in PTHrP, despite being 
hypocalcemic.  Although there is partial compensation by PTH when PTHrP is lacking, 
PTHrP is unable to compensate for lack of PTH. This suggests that both PTH and PTHrP 
play a role in fetal bone and mineral homeostasis.  
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1.4.2.3 FGF23 
 
FGF23 is predominantly expressed in rat fetal osteoblasts, as well as in the thymus, liver 
and kidney. In mouse models, FGF23 is expressed as early as ED 12.5 in the heart and 
liver and appears later in the bone.127 Intact FGF23 levels in the fetus are similar to that of 
the maternal value during late pregnancy,102 which is increased from female pre-
pregnancy values by two fold.128 
 
Although there are no studies of radiolabeled FGF23, it appears that FGF23 does not 
cross the placenta because Fgf23 null fetuses have undetectable levels of FGF23, in 
comparison to their heterozygous mothers which have levels of circulating FGF23 
averaging 225 pg/mL.102 Further to this, WT fetuses borne of mothers that are 
heterozygous for phosphate regulating endopeptidase homolog x-linked ( Phex+/-,also 
known as Hyp+/-) mothers, which have an excess of FGF23, have normal levels of 
circulating FGF23 in comparison to WT fetuses borne of Ffg23+/- mothers, despite the 
excess in maternal FGF23.102  
 
Studies of absence or excess of fetal FGF23 have shown no differences in any measured 
parameters of bone and mineral homeostasis, including serum and amniotic fluid 
phosphorus, skeletal mineral content and morphology and placental phosphorus 
transport.102 This suggests that FGF23 is not an important regulator of fetal phosphorus 
homeostasis. Moreover, when WT mothers are challenged with a high phosphorus diet, 
fetuses maintain normal phosphorus and FGF23 levels, independent of their respective 
maternal values (unpublished).  
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There is currently little data on FGF23 in human fetuses. Based on the scant data 
available, FGF23 in the cord blood appears to be lower than maternal values, however, c-
terminal FGF23 values are increased.128 This may suggest that fetal FGF23 is plentiful in 
the fetal circulation, but is being rapidly cleaved which is producing elevated levels of 
non-functional c-terminal fragments in the circulation. Moreover, levels of Klotho, the 
co-receptor for FGF23 are increased by six-fold in the cord blood in comparison to adult 
or neonatal values.129 With little human data available, we must rely on what we know 
about the mouse model to help us understand FGF23’s role in the fetus.  
 
 
1.4.2.4 Calcitriol 
 
Although 25OHD readily crosses the placenta from mother to fetus, calcitriol typically 
circulates at less than 50 % of the maternal value in fetal rodents130-133 and pigs.80 The 
lower circulating calcitriol values in fetal mice compared to the maternal circulation may 
be explained by low levels of plasma PTH, high serum calcium and phosphorus, as well 
as increased 24OHase activity that are presented under normal fetal physiological 
conditions.93 
 
In spite of playing a critical role in bone and mineral metabolism in both the child and the 
adult, evidence from both animal models and human disorders indicate that the low levels 
of circulating fetal calcitriol are not detrimental to fetal mineral homeostasis and skeletal 
development.  Studies of severely vitamin D deficient rats 134-136, Cyp27b1 null pigs 80 
and Vdr null mice131,137 have consistently shown normal fetal serum calcium, phosphorus, 
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and PTH levels, as well as ash weight and skeletal mineral content. Cyp27b1 null mice 
are also normal at birth, but until now, there have been no studies in the literature of their 
serum chemistries and skeletal mineral content during fetal development.81,138  
 
The findings to date suggest that fetal calcium homeostasis and skeletal development and 
mineralization are independent of calcitriol and its receptor; however, the effect of 
absence of calcitriol still needs to be studied. The placenta provides calcium to the fetus 
without relying on calcitriol, and vitamin D deficient and Vdr null placentas express 
normal concentrations of the vitamin D dependent factors calbindin-D-9k and Ca2+-
ATPase, which are important for intestinal calcium absorption and calcium homeostasis 
in the adult. 131,139,140 
The effects of loss of Vdr on fetal bone and mineral homeostasis have been studied using 
two main Vdr knockout models; the Boston model and the Leuven model, both named 
after the cities in which they were developed. In the case of the Boston model, Vdr is 
disrupted by removal of exon 3, encoding the second zinc finger of the Vdr-binding 
domain.23 Studies of the Boston model, carried out in our lab, have shown that Vdr null 
offspring born of both Vdr+/- and Vdr null  mothers have normal serum calcium, 
phosphorus, PTH, ash weight, tibial morphology and mineral content.131 In the case of the 
Leuven model, exon 2 of the Vdr gene is removed, which encodes the first of two zinc 
fingers that are characteristic of nuclear receptors and required for DNA binding.141  The 
Leuven model results in a truncated VDR which is transcribed, translated and secreted 
and has abnormal signaling. Thus, the Leuven model is not a complete Vdr null. Studies 
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of this model looked at Vdr null fetuses borne of Vdr null mothers. Similar to the study of 
the Boston model, these fetuses also had normal parameters related to bone and mineral 
homeostasis.137 Thus, despite not being a true null, the Leuven model ultimately led to a 
similar phenotype as the Boston model which is a true null.   
 
Human data is consistent with the notion that calcitriol may not be necessary for normal 
fetal bone and mineral homeostasis. Circulating calcitriol levels in the human fetus mirror 
those of fetal rodents and pigs, with the fetal calcitriol levels being less than 50 % of the 
maternal values.142-146 Calcitriol synthesis in the fetus is thought to be suppressed by the 
high calcium, phosphorus and low PTH values within the cord blood.  Similar to 
observations from animal models of vitamin D deficiency, babies with severe vitamin D 
deficiency have normal serum calcium, phosphorus, PTH, and skeletal morphology and 
mineral content.93 This evidence from both animal models and human observations 
indicate that vitamin D, calcitriol or VDR are not required to maintain normal mineral 
homeostasis and skeletal development within the fetus.  
 
1.5 Renal mineral absorption and the amniotic fluid 
 
In the adult, the kidneys play a vital role in regulation of bone and mineral homeostasis 
through their ability to adjust the relative reabsorption and excretion of minerals in 
response to calciotropic and phosphotropic hormones, as well as being the main site of 
calcitriol synthesis.  It is likely that the kidneys play a lesser role in the fetus than the 
adult given: 1) the placenta plays a dominant role in the handling of mineral and calcitriol 
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synthesis, and 2) the excreted mineral is not being lost as it is in the adult.  Instead, the 
fetal urine makes up a large part of the amniotic fluid which is swallowed, absorbed and 
brought back into the fetal circulation.  Therefore, calcium and phosphorus filtered by the 
fetal kidneys can be partially reabsorbed into the circulation to maintain mineral 
concentrations in the blood. 
1.6 Role of the fetal intestines  
 
The contrast in the physiological role of calcitriol after birth compared to during fetal 
development may be due to the trivial role of the fetal intestines during gestation. Unlike 
in the adult, where the intestines play a considerable role in mineral metabolism, the fetus 
receives its mineral through active transport of calcium, phosphorus and magnesium 
across the placenta from the maternal circulation.93 The fetal intestines cannot be studied 
directly. However, pre-term babies (and animals) are the functional equivalent of fetuses, 
and they show passive absorption of mineral that is not calcitriol-responsive, and low 
expression of VDR.93  
 
1.7 Placental mineral transport 
Beyond the intestines, kidneys and skeleton which play prominent roles in the regulation 
of mineral homeostasis in the adult, the fetus has a unique organ, the placenta, which has 
a vital role in fetal mineral homeostasis. The placenta assumes many functions that are 
carried out by other organs in the adult, including acting like the fetal lungs, disposing of 
fetal waste, hormone production as well as other functions. The placenta is responsible 
for the transport of calcium and other minerals from the mother to the fetus.121,147,148 
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Placental mineral transport may occur via simple diffusion, paracellular transport, 
vesicular transport or active transport.121   
Calcium transport across the placenta is thought to be similar to the passage of calcium 
across intestinal cells. TRPV6 channels open on the maternal-facing basement membrane 
of the placenta to allow calcium entry into placental cells, calcium shuttles across to the 
opposite basement membrane via Calbindin-D9k and is extruded into the fetal circulation 
by Ca2+ ATPase.93  The roles of these proteins in placental calcium transport are 
supported by data from fetal animal studies. Fetuses lacking either TRPV6 or PTHrP have 
reduced placental calcium transport, as well as a decrease in Calbindin-D9k, within the 
placental yolk sac.149,150However, it is not known whether the reduced placental calcium 
transport is directly or indirectly caused by the decrease in expression of Calbindin-D9k.  
Ca2+ ATPase has also proven to be important in placental calcium transport, as its 
knockdown leads to reduced calcium transport within the rat placenta.151,152 
Less is known about phosphorus transport across the placenta. But, it is known that the 
placenta expresses many phosphorus regulating genes including sodium phosphate 
transporters Napi2a, Napi2b, Napi2c, as well as low expression of Fgf23.102  
 
 
1.8 Role of calcitriol in placental function  
 
The role of calcitriol in placental function remains unclear. While the expression of Vdr, 
Cyp27b1 and calcitriol dependent calcium-transporting factors Pmca1,  S100G, and Trpv6 
in placental trophoblasts suggest calcitriol may play a role in placental function, studies in 
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vitamin D deficient fetal rats139 observed normal placental calcium transport. 
Interestingly, however, when fetal mice are exposed to pharmacological doses of 
calcitriol, placental calcium transport is increased.93 
 
Both the Boston and Leuven Vdr knockout models have shown high levels of circulating 
calcitriol in the Vdr null fetuses. 131,137 Interestingly, studies of the Boston model have 
shown that both Vdr null fetuses borne of Vdr+/- and of Vdr null mothers display a non-
significant trend towards increased placental calcium transport that became significant 
when results from these studies were pooled.131 Vdr null fetuses from Vdr+/- mothers were 
also shown to have increased expression of placental Trpv6 and increased expression of 
Pthrp as demonstrated through both immunohistochemistry and gene expression studies. 
Similarly, in studies of the Leuven model, Vdr null fetuses were shown to have 
significantly increased placental calcium transport and placental expression of Trpv6 in 
comparison to their Vdr+/- littermates, although no differences in placental expression of 
Pthrp were evident.  
 
The higher rate of placental calcium transport in Vdr null fetuses of both the Boston and 
Leuven models may indicate that if calcitriol does have a role, it may be to reduce 
placental calcium transfer, such that in the absence of VDR, calcium transport increases 
due to loss of calcitriol’s “brake” on the transport of mineral from the maternal to fetal 
circulation. Alternatively, since Vdr null fetuses have higher than normal concentrations 
of calcitriol,153,154 and since pharmacological treatment with calcitriol stimulated placental 
calcium transport in other studies,93 it is conceivable that calcitriol acts through non-
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classical receptors to upregulate placental calcium transport despite the absence of VDR. 
Therefore, the Vdr models do not definitively address the action of calcitriol.  
 
1.9 Rationale, hypothesis and objectives   
 
It is well known that calcitriol plays a significant role in bone and mineral homeostasis in 
the adult. However, less is known about the role of calcitriol in fetal bone and mineral 
homeostasis. Studies from Vdr null fetuses suggest that calcitriol is not required, but the 
high levels of circulating calcitriol and upregulated placental function in these fetuses left 
uncertainties that may be answered by studying fetuses that cannot synthesize calcitriol. 
 
There are three parts to our hypothesis: 
(1) Calcitriol is not required to maintain bone and mineral homeostasis in the fetus.  
(2) The upregulation of placental function in the Vdr null fetuses may be due to calcitriol 
having physiological effects to reduce placental calcium transfer, such that when 
calcitriol has no receptor to signal through, calcium transport increases due to loss of 
calcitriol’s normal effects as a “brake” on the forward flow.   
(3) Alternatively, since Vdr null fetuses have higher than normal concentrations of 
calcitriol, it is conceivable that such high levels of calcitriol act through non-classical 
receptors to upregulate placental calcium transport despite the absence of VDR. Such 
an action might not be physiological but only brought about with high concentrations 
of calcitriol, and this would explain why both Vdr null fetal mice and fetal sheep 
treated with pharmacological doses of calcitriol had increased placental calcium 
transport. 
 45 
 
Hypotheses were tested using a Cyp27b1 mouse knock out model, which lack the enzyme 
necessary to synthesize calcitriol. Cyp27b1 null and WT sisters were mated to Cyp27b1+/- 
males in order to study null and Cyp27b1+/- fetuses borne of null mothers, as well as WT 
and Cyp27b1+/- fetuses borne of WT mothers.  
 
The objectives of this research were to determine whether loss of calcitriol in Cyp27b1 
null fetuses of null mothers when compared to their siblings and to fetuses of related WT 
mothers: 
1. Alters serum minerals, calciotropic hormones, or amniotic fluid mineral content. 
2.  Alters skeletal morphology, ash weight, or skeletal mineral content. 
3.  Alters the rate of placental 45Ca transport from mother to fetuses. 
4.  Alters expression of relevant genes within placenta and kidneys. 
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II. Materials and Methods 
 
2.1 Animal husbandry  
2.1.1 Murine model 
Cyp27b1 null mice were provided by Dr. René St-Arnaud of McGill University in 
Montreal, Quebec.  The 1αOHase enzyme was inactivated by Cre-mediated excision of 
the gene in embryonic stem cells. Homologous recombination with the 1αOHase locus 
and wild-type locus generated a targeted allele in which exon 8, encoding the heme-
binding domain, was deleted, effectively generated a null allele.81 The mice were 
maintained in the C57BL/6 parent strain, through heterozygous matings, resulting in the 
generation of offspring of three genotypes: wild type (WT) with both normal Cyp27b1 
alleles (Cyp27b1+/+), heterozygous (Cyp27b1+/-) with one normal Cyp27b1 allele and one 
Cyp27b1 allele ablated, and Cyp27b1 null with both Cyp27b1 alleles ablated (Cyp27b1-/-).  
 
In a previous study in our lab, a traditional breeding approach was used in which 
Cyp27b1+/- males and females were mated so that WT, Cyp27b1+/- and Cyp27b1 null 
fetuses were generated in each litter. However, surprisingly, the Cyp27b1 null fetuses had 
detectable levels of circulating calcitriol. 
 
Therefore, in order to obtain truly calcitriol-deleted fetuses, Cyp27b1 null and WT 
mothers, first degree relatives of each other, were mated to the same Cyp27b1+/- males. 
This resulted in Cyp27b1 null and Cyp27b1+/- fetuses from Cyp27b1 null mothers, and 
Cyp27b1+/- and WT fetuses from WT mothers (Figure 9). Comparison of Cyp27b1 null 
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and WT fetuses conceivably revealed any effects of calcitriol deficiency, whereas 
comparison of Cyp27b1+/- fetuses from two different maternal backgrounds enabled 
detection of any maternal influence on the fetal phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
 
 
Figure 9: Mating Scheme. The traditional mating scheme of mating Cyp27b1+/- males to 
Cyp27b1+/- females could not be used as null fetuses obtain calcitriol from their HET 
mother.  Therefore, Cyp27b1+/- males were mated to either WT or Cyp27b1 null females 
in order to produce litters containing WT and Cyp27b1+/-or Cyp27b1 null and Cyp27b1+/- 
fetuses respectively.   
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2.1.2 Rescue diet   
 
Both WT and Cyp27b1 null female mice were placed on a rescue diet (TekLad 
TD.94112; Harlan TekLad, Madison, WI) consisting of 2% calcium, 1.25% phosphorus, 
and 20% lactose.155 The diet’s high lactose content increases paracellular calcium 
absorption138 and it has been used in prior studies of Cyp27b1 null and Vdr null mice to 
normalize fertility.156 The diet was provided ad libitum at weaning to allow for normal 
bone phenotype and fertility in the null mice.  
 
2.1.3 Timed mating 
 
Virgin first-degree relative pairs of WT and Cyp27b1 null females were mated with 
Cyp27b1+/- males at approximately 16:00 hours on Thursday evenings. At approximately 
9:00 hours the following morning, mice were checked for the presence of a vaginal 
mucus plug. The presence of a vaginal plug was indicative that the mouse had mated and 
may have conceived; if so, this was embryonic day (ED) 0.5. However, a plug was not 
always evident due to the plug being too small or the plug having fallen out. Mice were 
returned to their original cages and continually mated on Thursday evenings until 
pregnancy was visually confirmed. The normal gestational period for these mice was 18.5 
days.  
2.1.4 Animal housing  
Animals were housed in a facility operated by Animal Care Services of Memorial 
University of Newfoundland. Animals were housed in individually ventilated rodent 
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cages with 501 cm2 floor area (GM500, Techniplast Canada) and Bed-O-Cobs corn cob 
absorbent bedding (The Andersons, Maumee, OH, USA). This is in accordance with the 
Canadian Council on Animal Care (CCAC). The regular light and dark cycle was used 
with light from 8:00 hours to 20:00 hours.  
  
2.1.5 Animal care approval  
All experimental procedures were approved by the Institutional Animal Care Committee 
(IACC) of Memorial University of Newfoundland. 
 
 
2.2 Genotyping  
2.2.1 Animal identification  
At 21 days of age (the time of weaning), experimental mice were weaned from their 
mothers and separated into cages based on sex, with a maximum of 4 mice per cage. Mice 
were briefly anesthetized with Isoflurane (Baxter, Deerfield, IL), and their right ear was 
crimped with a tag for identification purposes. 
 
2.2.2 Tail sample collection  
While still under anaesthesia from the ear tagging procedure, a 0.5cm section of tail was 
clipped from each mouse with a sterile razor blade and placed into a labelled 1.5 mL 
Eppendorf tube. To digest tail clippings, 300 µl of cell lysis solution and 1.5 µl of 
proteinase K (Invitrogen, Carlsbad, CA) was added to each tube and tubes were placed in 
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an incubator (Thermo Fisher Scientific, Burlington, ON) for 18-24 h at 55 ˚C. Following 
this incubation period, tails were fully digested and ready for DNA extraction.  
 
2.2.3 DNA extraction  
DNA extraction was completed as per the Qiagen Purgene® Core A Kit (Qiagen, 
Toronto, ON). A protein precipitation solution (100 ul) was added to each digested tail 
sample and each sample was then vortexed for 20 sec at high speed. Samples were then 
centrifuged at 16,000 x g for 3 min in an IEC Micromax centrifuge (Thermo Fisher 
Scientific, Burlington, ON). Following centrifugation, each tube was checked for the 
presence of a white protein pellet and 300 µl of supernatant from each sample was 
pipetted into fresh 1.5 mL microcentrifuge tubes containing 300 µl of isopropanol. Tubes 
were gently inverted 50 times to precipitate the DNA, and then centrifuged for 1 min at 
16,000 x g to obtain the DNA in a small white pellet at the bottom of each tube. 
Following centrifugation, the supernatant was decanted and 300 µl of 70 % ethanol was 
added to each sample. Tubes were then inverted several times in order to wash the DNA 
pellet, following which they were centrifuges for 1 min at 16,000 x g. The supernatant 
was again decanted and excess ethanol was removed with a pipette. Tubes were left to air 
dry for 5 minutes to further allow the ethanol to evaporate off. Finally, 200µl of DNA 
hydration solution was added to each sample, samples were vortexed for 5 seconds and 
incubated at 65 degrees Celsius (ºC) for 1 hour in order to dissolve the DNA. 
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2.2.4 Polymerase chain reaction (PCR) 
PCR was carried out on the extracted DNA. In order to distinguish Cyp27b1 null, 
Cyp27b1+/- and WT mice, a 3-primer system was used:  
         Cyp27-1 (forward): 5’ - AAT TCC CGT CCA GAC AGA GAC ATC C – 3’ 
         Cyp27-2 (reverse): 5’ – GGT CAT GGG CTT GAT AGG AGC ACC – 3’ 
         Cyp27-3 (reverse): 5’ – GGG TGG GGA ATG TGA AGA AGA GGA TCT G – 3’ 
 
The PCR master mix was made with 10x PCR reaction buffer, deoxyribose nucleotide tri-
phosphates (dNTPS - dATP, dTTP, dCTP, dGTP), primers (Cyp27-1, Cyp27-2, Cyp27-3), 
50 mM MgCl2, Platinum Taq DNA polymerase, and distilled water (Invitrogen, Carlsbad, 
CA). The PCR master mix was aliquoted into fresh 0.2 mL PCR tubes (Thermo Fisher 
Scientific, Burlington, ON) with 19.5 µl in each. Next, 2 µl of DNA sample was then 
added into the solution in each tube. PCR tubes were then placed into Bio-Rad C1000 
Thermal Cycler (Bio-Rad Laboratories, Hercules, California). 
 
The PCR running program consisted of 7 steps, described as follows: Step 1: 94 °C for 5 
min for initial denaturation, Step 2: 94 °C for 30 sec to denature the DNA, Step 3: 58 °C 
for 30 sec for annealing, Step 4: 72 °C for 30 sec for elongation of complementary strand, 
Step 5: return to step 2 and repeat for 35 cycles for continued amplification, Step 6: 72 °C 
for 10 min to elongate any remaining strands and Step 7: 4 °C infinitely for storage of 
reaction.  
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2.2.5 Gel electrophoresis  
Gel electrophoresis was completed in order to separate and display PCR products. A     
1.2 % agarose gel was made using 10 mL TAE buffer (0.12 M EDTA, 0.40 M Tris, 11.5 
% Glacial Acetic Acid, pH 8), 90 mL deionized water, 1.2 g agarose (Invitrogen, 
Carlsbad, CA) and 10 µl of SYBR Safe DNA Gel Stain (Invitrogen, Carlsbad, CA). 
Agarose powder was added into the TAE buffer solution and then melted by microwaving 
in two separate 1 min intervals. Next, SYPBR safe gel stain was added to the solution and 
gently swirled. The solution was poured into the gel casting tray, containing 2 gel comb 
inserts, and allowed to solidify. While the gel was solidifying, 4 µl of gel loading dye 
[1mL Tris, 0.03 g bromophenol blue, 0.03 g xylene cyanol FF, 60 mL glycerol, 12 mL of 
0.5 M EDTA, 27 mL deionized water (dH20)] was added to each PCR tube.  
 
Once the gel had solidified, gel running buffer [90 mL 10x TAE and 810 mL dH20] was 
added to the gel electrophoresis chamber and gel comb inserts were carefully removed. 
Fifteen µl of PCR product and gel dye mixture was injected into each well of the gel. The 
samples were run at 200 V for 20 min.  
 
Following electrophoresis, the bands were visualized under UV light using the Kodak Gel 
Doc System (Bio-Rad, Hercules, CA). The results were analyzed using Bio-Rad Image 
lab software (Bio-Rad, Hercules, CA). A single 250 bp band indicated WT mice, a single 
350 bp band indicated null mice and bands at both 250 bp and 350 bp indicated HET 
mice (Figure 10).  
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Figure 10: Genotyping by Polymerase Chain Reaction and Gel Electrophoresis. 
Sample PCR products run on a 1.2 % agarose gel. The presence of a single band at 250 bp 
indicates a WT mouse, presence of both 250 bp and 350 bp bands indicates a Cyp27b1+/- 
mouse, and the presence of a single 350 bp band indicates a Cyp27b1 null mouse.  
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2.3 Sample collection and storage 
 
2.3.1 Serum collection 
On ED 18.5, maternal blood serum samples were collected by bleeding the tail vein.  A 
small clipping of tail was cut with a sterile razor blade and the blood was massaged out 
into a 0.6 mL micro centrifuge tube (Thermo Fisher Scientific, Burlington, ON). Under 
brief anesthesia using Isoflurane (Baxter, Deerfield, IL), mothers were then euthanized 
via cervical dislocation. Fetuses were removed via Caesarean section (C-section) and 
were detached from their placentas by severing their umbilical cords. Fetal blood was 
collected by making a small incision in the carotid artery and jugular vein using a sterile 
razor blade and blood was collected into a Micro-Hematocrit Capillary Tube (Fisher 
Scientific, Burlington, ON). Following fetal blood collection, fetuses were immediately 
euthanized by decapitation. Blood samples were subsequently spun on a microcentrifuge 
for 5 min at 16,000 x g to separate out serum from clotted blood. Serum was stored at        
-20 °C for future analysis.  
2.3.2 Amniotic fluid collection  
On ED 17.5, mothers were sacrificed by cervical dislocation and pups were removed by 
C-section. Each amniotic sac was lanced using a 20G needle (BD PrecisionGlide™) and 
the fluid was collected in 60 µl micro-hematocrit capillary tubes (Thermo Fisher 
Scientific, Burlington, ON). Samples were then transferred to 0.6 ml microcentrifuge 
tubes (Fisher Scientific, Burlington, ON) and stored at – 20 °C until analysis.  
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2.3.3 Collection of placenta and fetal kidneys 
On ED 18.5, following detachment of the fetus from the placenta, placentas were 
individually placed into 1.5 mL Eppendorf tubes and were flash frozen in liquid nitrogen. 
Serum was then collected and fetuses were euthanized. Following euthanasia, fetuses 
were laid in a supine position and a small incision was made from the pelvic bone to the 
sternum. Both kidneys were then removed from each fetus, placed into a 1.5mL 
Eppendorf tube and flash frozen in liquid nitrogen. Tissues were stored at -70 ºC for 
future analysis.  
2.3.4 Collection of whole bodies 
On ED. 18.5, following removal of fetal kidneys, fetal bodies were placed in labelled 
scintillation vials containing 10 % buffered formalin (1x PBS, 4 % Formaldehyde, dH2O) 
and stored at room temperature. Once all samples had been collected, fetuses were 
removed from vials, the right hind limb was removed and placed back into the buffered 
formalin for embedding in paraffin.  
 
2.4 Analysis of serum and amniotic fluid mineral content 
2.4.1 Serum and amniotic fluid total calcium measurement  
Serum (ED 18.5) and amniotic fluid (ED 17.5) total calcium were measured using a 
calcium assay (Sekisui Diagnostics, Charlottetown, PEI). The assay is based on the 
principle that Arsenazo III reacts with calcium to form a complex that is blue-purple in 
color with a maximum absorbance of 650 nm. Therefore, results read at this wavelength 
are directly proportional to the total calcium concentration in the sample. The reportable 
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range for this kit was 0.01 mmol/L to 3.75mmol/L. Serum and amniotic fluid samples 
were measured undiluted and following kit protocol. A spectrophotometer (Ultraspec 
2000; Pharmacia Biotech, Piscataway, NJ) was used to measure samples at an absorbance 
of 650 nm. Deionized water was used as a blank.  
2.4.2 Serum and amniotic fluid inorganic phosphate measurement  
Serum (ED 18.5) and amniotic fluid (ED 17.5) inorganic phosphate were measured using 
a Phosphorus-SL assay (Sekisui Diagnostics, Charlottetown, PEI). The assay is based on 
the principle that inorganic phosphorus reacts with ammonium molybdate in the presence 
of sulfuric acid to produce an unreduced phosphomolybdate complex. The concentration 
of inorganic phosphorus in the sample is directly proportional to the absorbance at 320 
nm.  The reportable range of the kit was 0.03 mmol/L to 6.46 mmol/L. Serum and 
amniotic fluid samples were measured undiluted and following kit protocol. A 
spectrophotometer (Ultraspec 2000; Pharmacia Biotech, Piscataway, NJ) was used to 
measure samples at an absorbance of 320 nm. Deionized water was used as a blank. 
2.5 Hormone physiology  
2.5.1 Serum calcitriol  
Serum calcitriol was measured using a 1,25-dihydroxy vitamin D enzyme-immunoassay 
(EIA) Kit (Immunodiagnostic Systems, Maryland, USA). The detection limit for the 
assay in human serum was 6 pmol/L. The manufacturer has not published the detection 
limit in mice. The assay was carried out over a two-day period. The calcitriol in the 
samples was first purified by immunoextraction then quantified by EIA. The principle of 
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the assay was based on competitive binding of either free calcitriol or calcitriol linked to 
biotin for a limited amount of highly specific sheep anti-calcitriol antibody binding sites. 
The amount of complexed biotin bound to the anti-sheep antibody was inversely 
proportional to the concentration of free calcitriol. Due to the amount of fetal serum 
needed for each sample, the assay was carried out using a 1:2 dilution of serum in PBS 
supplemented with 1% BSA. Maternal and fetal serum samples were measured. The 
remaining assay procedure followed kit protocol for “alternative sample preparation” and 
remaining immunoextraction assay procedure. Any values that were below the assay 
sensitivity were reset to values that equaled the assay’s detection limit. 
 
2.5.2 25-Hydroxyvitamin D and 24,25-dihydroxyvitamin D 
Maternal and fetal serum were sent to Dr. Glenville Jones at Queen’s University in 
Kingston Ontario for the measurement of 25-OHD3 and 24,25-dihydroxyvitamin D3. 
Samples were measured using liquid chromatography tandem mass spectrometry. The 
assay methods, details and procedure have been previously published. 157 
 
2.5.2 Serum parathyroid hormone (PTH) 
Serum PTH was measured using a Mouse Intact PTH ELISA Kit (Immunotopics Inc., 
San Clement, CA). The detection limit of the assay was 4 pg/mL. The assay principle is a 
two-site enzyme-linked immunosorbent assay (ELISA) . Samples were incubated 
simultaneously with a biotinylated capture antibody and a horseradish peroxidase (HRP) 
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conjugated antibody in a streptavidin coated microtiter well. Intact PTH contained in the 
sample is immunologically bound by the capture antibody and the detection antibody to 
form a sandwich complex. The enzymatic activity of the antibody complex bound to the 
well is directly proportional to the amount of PTH in the sample.  Samples were measured 
using an Epoch Microplate Spectrophotometer (Biotek) at an absorbance of 450 nm. 
Maternal and fetal serum collected on ED 18.5 were measured and experiments were 
completed as per kit protocol. Any values that appeared to be below the assay sensitivity 
were reset to values that equaled the assay’s detection limit. 
2.5.3 Serum fibroblast growth factor 23 (FGF23) 
Serum FGF23 was measured using a FGF23 ELISA Kit (Kainos Laboratories, INC., 
Tokyo, Japan) designed for measurement of mouse serum. The detection limit of the 
assay is 3 pg/mL. The assay principle is a two-step enzyme-linked immunosorbent assay. 
In the first reaction, samples are incubated with the immobilized antibody in a microtiter 
well, allowing the FGF23 in the samples to be captured by the antibody. In the second 
reaction, the immobilized FGF23 is incubated with HRP labelled antibody to form a 
sandwich complex. The enzymatic activity of the antibody complex bound to the well is 
directly proportional to the amount of FGF23 in the sample. Samples were measured 
using an Epoch Microplate Spectrophotometer (Biotek, Winooski, VT). Maternal and 
fetal serum collected on ED 18.5 were measured and experiments were completed as per 
kit protocol. Any values that appeared to be below the assay sensitivity were reset to 
values that equaled the assay’s detection limit. 
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2.6 Histomorphometry  
 
Undecalcified, paraffin embedded hind limbs, collected from WT and Cyp27b1 null 
fetuses, were sectioned into 5 μm sections with a Leica RM2135 rotary microtome (Leica 
Microsystems, Wetzlar, Germany). Tibia sections were placed on a slide warmer (Fisher) 
for 30 min and samples were then deparafinized and rehydrated using the following 
protocol: Step 1: Xylene for 2 min (2x), Step 2: 100 % Ethanol (EtOH) for 2 min (2x), 
Step 3: 95 % EtOH for 2 min, Step 5: 70 % EtOH for 2 min, Step 6: 50 % EtOH for 2 min 
and Step 7: distilled water for 1 min.  Sections were then stained with methyl green 
(Sigma, Kawasaki, Japan) for 15 min. Excess dye was blotted from the slides, washed in 
1-butanol (Fisher Scientific, Burlington, ON) for 10 sec (2x), and then washed in xylene 
for 10 sec (2x). Cover slips were then mounted on each slide using Permount (Fisher 
Scientific, Burlington, ON). Stained tibial sections were viewed using a Leica DM500 
LED Optical Microscope at 10x magnification (Leica, Wetzler, Germany). Images were 
taken using a Sony DXC-S500 color digital camera (Sony, Tokyo, Japan).  
 
 
2.7 Fetal ash and mineral content  
 
Individual fetuses were weighed, placed in crucibles and reduced to ash in a furnace at 
500 °C for 24 h. Following cremation, the ash was removed from the crucibles using a 
fine paintbrush and weighed.  The ash weight reflects the amount of total mineral present 
in the fetal skeleton. Ash samples were then transferred into acid washed 20mL glass 
scintillation vials and stored at room temperature until samples were prepared for 
analysis. Before analysis, 253 µl of nitric acid was added to each scintillation vial 
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containing fetal ash and samples were left at room temperature for 5 days to dissolve. 
Following dissolution of the ash, 9.75 mL of deionized water was added to each vial. 
Skeletal calcium and magnesium content were measured using the 2380 Atomic 
Absorption Spectrophotometer (Perkin –Elmer, Waltham, MA). Appropriate dilutions 
were used to allow the reading to be within the proper calibration range. Skeletal 
phosphorus content was measured using a Phosphorus-SL assay (Sekisui Diagnostics, 
Charlottetown, PEI) as per kit protocol.  
 
2.8 Gene expression  
2.8.1 RNA extraction  
RNA was extracted from placentas and fetal kidneys using the RNeasy® Lipid Tissue Kit 
(QIAGEN, Toronto, ON).  Tissues were homogenized in bead tubes containing 10 beads 
and QIAzol Lysis Reagent (QIAGEN, Toronto, ON) using Precellys® Tissue 
Homogenizer. Following homogenization, chloroform was added to each sample, and 
samples were centrifuged to separate homogenate into aqueous and organic phases. The 
upper, aqueous phase was then collected, and 70 % ethanol was added to provide 
appropriate binding conditions. The sample was then applied to an RNeasy spin column, 
where total RNA binds to the membrane, and phenol and other contaminants are removed 
through washing with buffer RW1, and with buffer RPE (2x). RNA was then eluted in 
RNase-free water. The RNeasy® Lipid Midi Tissue Kit (QIAGEN, Toronto, ON) was 
used for extraction of RNA from placentas (≤250 mg of tissue), while the RNeasy® Lipid 
Mini Tissue Kit was used for extraction of kidney RNA (≤ 30 mg of tissue). 
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2.8.2 Synthesis of complementary DNA (cDNA)  
cDNA was synthesized using a High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Burlington, ON) using 2 µg of mouse placental or fetal kidney mRNA. 
Experimental procedure followed kit protocol.  
 
The synthesis program conditions were as follows: Step 1: 25 °C for 10 min; Step 2:      
37 °C for 120 min; Step 3: 85 °C for 5 min; Step 4: hold at 4 °C for infinity. Synthesis 
program was carried out using a Bio-Rad C1000 Touch Thermal Cycler (Bio-Rad 
laboratories, Hercules, California). 
2.8.3 Real –time quantitative reverse transcriptase-PCR (RT qPCR) 
RT qPCR was completed using the following Taqman® Gene Expression Assays 
(ThermoFisher Scientific, Burlington, ON): Cyp27b1, Cyp24a1, Pmca1, VDR, S100G, 
Pthrp, Trpv6, and NaPi 2a, NaPi 2b and NaPi 2c. These assays are pre-designed and pre-
optimized with a fluorogenic probe with a FAM™ dye label on the 5' end and a non-
fluorescent quencher on the 3' end. When targeted cDNA was amplified, the MGB probe 
was digested by DNA polymerase and the FAM reporter dye was released. Fluorescence 
from free FAM reporter dye was detected by the real-time PCR system. The intensity of 
fluorescence was directed to the concentration of targeted cDNA within proper range. 
The thermal cycler protocol consisted of the following steps: Step 1: 50 °C for 2 min for 
Uracil-N-Glycosylase (UNG) incubation; Step 2: 95 °C for 20 sec for polymerase 
activation; Step 3: 95 °C for 1 sec to denature; Step 4: 60 °C for 20 sec for annealing; 
Step 5: Return to step 3 and repeat 40 times.  Multiplex qPCR reactions (gene of interest 
multiplexed with reference gene) were run in triplicate on the ViiA™ 7 Real-Time PCR 
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System (Fisher Scientific, Carlsbad, CA). Technical replicates (triplicate) of each sample 
were used with a reaction volume of 20 µl. Relative expression was determined from the 
threshold cycle (CT) normalized to the reference gene (Gapdh). Gapdh was labelled with 
Vic reporter dye, and was measured using a Taqman® Gene Expression Assay. 
 
 
2.9 Placental calcium transport  
 
On ED 17.5, mothers were briefly anesthetized with Isoflurane and received an 
intracardiac injection of 100 µl of 45Ca and 51Cr-EDTA cocktail. EDTA is passively 
transferred and serves as a blood diffusional marker. The cocktail was made up of 1.85 
megabecquerels (MBq) of 45Ca, 1.85 MBq of 51Cr and the remaining volume of saline. 
After 5 min, mothers were sacrificed by cervical dislocation and fetuses were removed 
via C-section. Tails from each fetus were collected for genotyping. Fetuses were 
sacrificed by pithing the skulls and were placed in plastic tubes for measurement of 
radioactivity. The 51Cr activity was measured using a 1480 WIZARD 3 automatic gamma 
counter (Perkin Elmer, Waltham, MA). Fetuses were then transferred into scintillation 
vials containing 10 mL of Scintigest and placed in an incubator at 55 ˚C for 24-48 h to 
solubilize. Following the incubation period, 10 mL of scintillation fluid and 5 drops of 
glacial acetic acid were added to each vial and vials were covered in aluminum foil and 
placed in the dark for 24 h to prevent bioluminescence.125 The activity of 45Ca was 
measured with a LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter, Brea, 
CA). Placental calcium transport was expressed as a ratio of 45Ca/51Cr in each fetus, 
normalized to the mean value of heterozygous fetuses within each litter. 
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2.10 Statistical analysis  
 
Data were analyzed using StatPlus: Mac Professional 2009, Build 6.0.3 (AnalystSoft Inc., 
Vancouver, BC).  ANOVA (analysis of variance) was used for analysis of biochemical, 
transport, and ash data, with Tukey-Kramer post-hoc to determine which pairs of means 
differed significantly.  qPCR data was analyzed using the Comparative CT method 
(2∆CT)158. All data are presented with mean ± standard error (SE) for fetal data except 
mean ± standard deviation (SD) for qPCR. On the graphs, significant differences are 
marked, and the number of observations is indicated in parentheses on the x-axis. 
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III. RESULTS 
 
 
3.1 Litter size  
 
The number of fetuses present in WT and Cyp27b1 null mothers was determined at ED 
18.5. It is an indicator of fertility and the capacity of the mother to carry fetuses to term. 
Litter sizes were no different between the maternal genotypes, specifically 8.3±0.5 in 
Cyp27b1 null vs. 8.1±0.3 in WT mothers.  
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Figure 11: Average litter size of fetuses borne of WT and Cyp27b1 null mothers. 
Litter sizes were no different between litters borne of Cyp27b1 null mothers and litters 
borne of WT mothers. Values are means ± SE and the number of observations are 
indicated in parentheses. 
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3.2  Hormone physiology  
 
The fetal serum concentrations of several hormones relevant to calcium and phosphorus 
homeostasis were determined. 
3.2.1 Calcitriol   
We measured calcitriol first, in order to confirm that it is absent in Cyp27b1 null fetuses 
born of Cyp27b1 null females.  
 
Serum calcitriol levels in null fetuses were 16 pmol/L was not significantly different from 
the published detection limit for human sera (6 pmol/L). It may represent the detection 
limit for mouse sera, which has not been formally established (Figure 12). The kit uses 
anti-mouse antibodies, and as a consequence, non-specific binding within mouse sera can 
be expected to raise the detection limit. 
  
Cyp27b1 null mothers had detectable calcitriol (167 ± 70 pmol/L), but significantly lower 
than levels found in related WT mothers (719 ± 79 pmol/L). 
 68 
 
 
Figure 12: Serum calcitriol in WT and Cyp27b1 null mothers and their fetuses. 
Cyp27b1 null fetuses have levels of calcitriol that are lower than the expected detection 
limit. Maternal calcitriol is lower in null mothers compared to WT mothers. The dashed 
line represents the expected detection limit of the assay for mouse sera. Values are means 
± SE and the numbers of observations are indicated in parentheses.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT DAM  NULL DAM  
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3.2.2 25OHD and 24,25-dihydroxyvitamin D 
Calcitriol is formed by hydroxylation of 25OHD, and both 25OHD and calcitriol are 
catabolized by 24-hydroxylation. In this process 25OHD is converted to the inactive 
form, 24,25-dihydroxyvitamin D. Calcitriol stimulates its own catabolism via Cyp24a1. 
The absence of calcitriol in Cyp27b1 null fetuses could result in accumulation of its 
precursor or altered rate of catabolism by Cyp24a1.  Therefore, we measured these 
metabolites of vitamin D as well, specifically the D3 isoforms.  
 
Both 25OHD3 and 24,25-dihydroxyvitmain D were no different between Cyp27b1 null 
fetuses and their Cyp27b1+/- littermates. However, these metabolites were significantly 
higher in these fetuses in comparison to both WT and Cyp27b1+/- fetuses borne of WT 
mothers.  
 
 
 
 
 
 
 
 
 
 70 
 
Figure 13: Serum 25OHD3. Serum 25OHD3 was significantly higher in fetuses born of 
null mothers when compared to fetuses born of WT mothers, whereas there were no 
differences between litters. This suggests that maternal calcitriol may be an important 
direct or indirect determinant of fetal 25OHD3. Values are means ± SE and the numbers 
of observations are indicated in parentheses. 
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Figure 14: Serum 24,25-dihydroxyvitamin D. Serum 24,25-dihydroxyvitamin D was 
significantly higher in fetuses born of null mothers when compared to fetuses born of WT 
mothers, whereas there were no differences between litters. This suggests that maternal 
calcitriol may be an important direct or indirect determinant of fetal 24,25-
dihydroxyvitamin D. Values are means ± SE and the numbers of observations are 
indicated in parentheses. 
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3.2.3 PTH 
Next, we wanted to measure PTH, as it is the main stimulator of calcitriol’s synthesis.  
 
There were no differences in PTH within or between litters. However, fetal serum PTH 
levels did display a nonsignificant trend towards lower values in fetuses borne of 
Cyp27b1 null mothers, in comparison to fetuses borne of WT mothers. This suggests that 
maternal calcitriol plays a direct or indirect role in regulating fetal PTH levels.  I am 
drawing your attention to this trend now, to support other results that follow. 
 
This data matches prior study of Vdr null fetuses which also had normal PTH levels in 
comparison to their WT counterparts. 131,137 
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Figure 15: Serum PTH in fetal mice borne of WT and Cyp27b1 null mothers. Serum 
PTH is no different between null and Cyp27b1+/- fetuses of null mothers, or when 
compared to WT and Cyp27b1+/- fetuses of WT mothers. Values are means ± SE and the 
numbers of observations are indicated in parentheses. 
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3.2.4 FGF23 
Calcitriol is a potent stimulator of FGF23 synthesis, and so loss of calcitriol's actions 
should also lower serum FGF23 levels.  FGF23 was not significantly different between 
Cyp27b1 null fetuses and their Cyp27b1+/- littermates.  However, both null fetuses and 
their Cyp27b1+/- littermates had significantly lower serum FGF23 than in Cyp27b1+/- 
fetuses born to WT mothers (Figure 16). This suggests that fetal calcitriol is not necessary 
for regulation of fetal FGF23. Instead, maternal calcitriol may directly or indirectly play a 
role in determining the fetal FGF23 concentration. 
 
This data contrasts with prior study of Vdr null fetal mice which indicated 50% lower 
serum FGF23 than their WT sisters.102  
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Figure 16: Serum FGF23 in fetal mice borne of WT and Cyp27b1 null mothers. 
FGF23 is lower in fetuses born of null mothers compared to Cyp27b1+/- fetuses born of 
WT mothers, whereas there were no differences within litters. This suggests that maternal 
calcitriol may be an important direct or indirect determinant of fetal FGF23. Values are 
means ± SE and the numbers of observations are indicated in parentheses. 
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3.3 Serum and amniotic fluid mineral concentrations 
 
Postnatally, in the absence of calcitriol, serum calcium and phosphorus become low, urine 
calcium becomes low and phosphorus excretion is increased. We wanted to investigate 
this in the fetus by determining amniotic fluid calcium and phosphorus values, which acts 
as a surrogate of renal excretion into the urine.  
3.3.1 Total serum calcium and amniotic fluid calcium measurement  
 
Serum calcium was no different between null fetuses and their Cyp27b1+/- littermates or 
when compared to Cyp27b1+/- and WT fetuses of WT mothers (Figure 17).  
 
Amniotic fluid calcium was no different between Cyp27b1 null fetuses and their 
Cyp27b1+/- littermates; however, the value was significantly increased in fetuses from 
Cyp27b1 null mothers as compared to the offspring of WT mothers (Figure 18). The 
normal amniotic fluid in the Cyp27b1 null fetuses in comparison to their Cyp27b1+/- 
littermates likely indicates that renal calcium excretion is normal. However, as both 
Cyp27b1 null and Cyp27b1+/- fetuses have increased amniotic fluid calcium in comparison 
to fetuses borne of WT mothers, maternal calcitriol may be an indirect or director 
determinant of amniotic fluid calcium. This also suggests that the trend towards lower 
PTH in fetuses from Cyp27b1 null mothers may be true, as lower PTH would be expected 
to lead to an increase in calcium excretion into urine and amniotic fluid, in keeping with 
what happens postnatally in the presence of low PTH. 
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This data coincides with prior study of Vdr null fetuses, that found normal amniotic fluid 
calcium in Vdr null fetuses in comparison to littermates. 131 
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Figure 17: Serum calcium in fetal mice borne of WT and Cyp27b1 null mothers. 
Serum calcium is no different between null and Cyp27b1+/- fetuses born of Cyp27b1 null 
mothers and WT and Cyp27b1+/- fetuses born of WT mothers. Values are means ± SE and 
the numbers of observations are indicated in parentheses. 
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Figure 18: Amniotic fluid calcium in fetal mice borne of WT and Cyp27b1 null 
mothers. Amniotic fluid calcium is significantly higher in fetuses born of Cyp27b1 null 
mothers compared to fetuses born of WT mothers. This suggests that maternal calcitriol is 
an important indicator of amniotic fluid calcium content. Values are means ± SE and the 
numbers of observations are indicated in parentheses. 
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3.3.2 Serum and amniotic fluid phosphorus measurement  
 
There was no difference in serum phosphorus concentrations between Cyp27b1 null and 
Cyp27b1+/- littermates or when compared to fetuses borne of WT mothers (Figure 18). 
 
Amniotic fluid phosphorus was no different between null and Cyp27b1+/- littermates.  
However, amniotic fluid phosphorus was significantly lower in fetuses from Cyp27b1 
null mothers, as compared to fetuses from WT mothers (Figure 19). The normal amniotic 
fluid phosphorus in the Cyp27b1 null fetuses in comparison to their Cyp27b1+/- littermates 
likely indicates that renal phosphorus excretion is normal. However, as both Cyp27b1 null 
and Cyp27b1+/- fetuses have decreased amniotic fluid phosphorus in comparison to fetuses 
borne of WT mothers, maternal calcitriol may be an indirect or director determinant of 
amniotic fluid phosphorus.  Moreover, these results also match the trend towards lower 
PTH in Cyp27b1 null fetuses, as lower PTH would cause a decrease in phosphorus 
excretion into urine and, thereby, amniotic fluid.  
  
This data is consistent with prior study of Vdr null fetuses had normal amniotic fluid 
phosphorus in comparison to their littermates.131 
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Figure 19: Serum Phosphorus in fetal mice borne of WT and Cyp27b1 null mothers.  
Serum phosphorus is no difference between null and Cyp27b1+/- fetuses born of null 
mothers and WT and Cyp27b1+/- fetuses born of WT mothers. Values are means ± SE and 
the numbers of observations are indicated in parentheses. 
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Figure 20: Amniotic fluid phosphorus in fetal mice borne of WT and Cyp27b1 null 
mothers. Amniotic fluid phosphorus is significantly lower in fetuses of Cyp27b1 null 
mothers when compared to fetuses of WT mothers. This suggests that maternal calcitriol 
plays a role in the regulation of fetal phosphorus excretion. Values are means ± SE and 
the numbers of observations are indicated in parentheses. 
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3.4 Fetal skeletal ash weight, mineral content and morphology  
 
Ultimately circulating mineral ends up in the skeleton; therefore, if loss of calcitriol 
affects mineral transport or accretion of mineral into the bone, this should be visualized in 
the skeleton. Furthermore, if calcitriol is important for osteoblast or osteoclast function, 
then altered skeletal development may be a measurable outcome. To address this, fetal 
ash weight, mineral content and morphology were assessed.   
 
3.4.1 Fetal ash weight and skeletal mineral content  
 
 
Ash weight is a reflection of the total mineral content within the fetal skeleton. There was 
no difference in ash weight between null and Cyp27b1+/- fetuses of Cyp27b1 null mothers 
(0.0151 ± 0.0008g vs. 0.0160 ± 0.0008g) or when compared to WT and Cyp27b1+/- 
fetuses of WT mothers (Figure 21).  
 
There were no differences in ash calcium (Figure 22), phosphorus (Figure 23) or 
magnesium (Figure 24) content in Cyp27b1 null fetuses compared to their Cyp27b1+/- 
littermates, or when compared to WT and Cyp27b1+/- littermates from WT mothers. 
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Figure 21: Ash Weight of fetal mice borne of WT and Cyp27b1 null mothers. Fetal 
ash weight was no different between null and Cyp27b1+/- fetuses of Cyp27b1 null 
mothers, or when compared to WT and Cyp27b1+/- fetuses of WT mothers. Values are 
means ± SE and the numbers of observations are indicated in parentheses. 
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Figure 22: Skeletal calcium content in fetal mice borne of WT and Cyp27b1 null 
mothers. Intact fetuses were reduced to ash and skeletal mineral content was measured 
using flame atomic spectrophotometry. Skeletal calcium content was no different between 
null and Cyp27b1+/- fetuses borne of Cyp27b1 null mothers or when compared to WT and 
Cyp27b1+/- fetuses of WT mothers. Values are means ± SE and the numbers of 
observations are indicated in parentheses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT DAM NULL DAM 
 86 
 
 
 
 
 
 
Figure 23: Skeletal phosphorus content of fetal mice borne of WT and Cyp27b1 null 
mothers. Intact fetuses were reduced to ash and skeletal mineral content was measured 
using flame atomic spectrophotometry. Skeletal phosphorus content was no different 
between null and Cyp27b1+/- fetuses borne of Cyp27b1 null mothers or when compared to 
WT and Cyp27b1+/- fetuses of WT mothers. Values are means ± SE and the numbers of 
observations are indicated in parentheses. 
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Figure 24: Skeletal magnesium content in fetal mice borne of WT and Cyp27b1 null 
mothers. Intact fetuses were reduced to ash and skeletal mineral content was measured 
using flame atomic spectrophotometry. Skeletal magnesium content was no different 
between null and Cyp27b1+/- fetuses borne of Cyp27b1 null mothers or when compared to 
WT and Cyp27b1+/- fetuses of WT mothers. Values are means ± SE and the numbers of 
observations are indicated in parentheses. 
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3.4.2 Tibial morphology  
To examine skeletal development, the morphology of the fetal tibiae were examined, as it 
is the gold standard methodology recognized by the literature. The sequential 
development is visually laid out with the identifiable zones of chondrocytes within the 
growth plate followed by the start of the endochondral bone.  
By use of this method, Cyp27b1 null fetal tibias showed normal endochondral 
development with no differences in length or cellular morphology compared to tibial 
sections from WT fetuses born of WT mothers (Figure 25). 
 
These results contrast with prior study of Vdr null fetuses which have shown increased 
placental calcium transport in the Vdr null fetuses compared to their Vdr+/- 
littermates.131,137 
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Figure 25: Fetal Tibial morphology. Cyp27b1 null fetuses (B) show normal 
endochondral development, with no alteration in the length and cellular morphology of 
cartilaginous or boney compartments (as shown by methyl green stain), in comparison to 
WT fetuses borne of WT mothers (A).  These images are representative of the individuals 
examined.  
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3.5 Placental calcium transport 
 
Thus far, Cyp27b1 null fetuses show no deficit in mineral concentrations in the 
circulation or accreted into the skeleton. We wanted to measure placental calcium 
transport to be certain that delivery of mineral to the fetus is also unaffected by absence of 
calcitriol, versus increased as it was in the Vdr nulls.  
 
Placental calcium transport was not altered between Cyp27b1 null and Cyp27b1+/- 
littermates or when compared to related Cyp27b1+/- and WT fetuses from WT mothers 
(Figure 26).  
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Figure 26: Placental calcium transport in fetuses borne of Cyp27b1 null and WT 
mothers. Five minutes following injection of 45Ca/51Cr-EDTA into the dam, Cyp27b1 
null fetuses showed the same amount of placental calcium transport as their Cyp27b1+/- 
littermates. Placental calcium transport was also no different when compared to WT and 
Cyp27b1+/-  fetuses of WT mothers. Values are means ± SE and the numbers of 
observations are indicated in parentheses. 
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3.6 Expression of placental genes as assessed by qPCR 
 
As there is normal placental calcium transport in Cyp27b1 null fetuses, it seems as if 
placental function is normal despite loss of fetal calcitriol. However, we examined 
placental function further to determine if absence of calcitriol leads to any alteration in 
the expression of placental genes that are involved in calcium or phosphorus transport.  
 
These genes were examined in placentas of Cyp27b1 null vs. Cyp27b1+/- littermates, as 
well as in WT vs. Cyp27b1+/- littermates (Table 1). Cyp27b1+/- placentas showed robust 
expression of Cyp27b1 which was absent in respective null placentas (1.000 ± 0.277 vs. 
0.0068 ± 0.006). Separate comparison of Cyp27b1 null vs. WT placentas showed absent 
expression of Cyp27b1 in the null placentas. 
 
There was no difference in expression of Trpv6 (Figure 27AB) or Pthrp (Figure 28AB) 
between null and Cyp27b1+/- placentas, or between null and WT placentas.  
 
Cyp24a1, Pmca1, S100g, Napi2a, Napi2b, Napi2c were all expressed in the placenta. 
There was a slight statistically significant decrease in expression of Pmca1 in Cyp27b1 
null placentas, that may be physiologically insignificant. There were no other differences 
evident between Cyp27b1 null and Cyp27b1+/- placentas, or between placentas of WT and 
Cyp27b1+/- littermates, for each of these genes (Table 1).  
 
Low expression of Fgf23 was present in Cyp27b1 null and Cyp27b1+/- placenta (High CT 
values of ~ 38 cycles). This corresponds with previous findings from our laboratory.  
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In contrast to the normal expression of Trpv6 and Pthrp in Cyp27b1 null placentas, 
previous study of Vdr null fetuses showed an upregulation in Trpv6131,137 and Pthrp131 in 
comparison to their littermates.  
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Table 1: Expression of genes related to calcium and phosphorus transport within the placenta 
of Cyp27b1 null fetuses versus their Cyp27b1+/- siblings and WT fetuses versus their Cyp27b1+/- 
siblings. Values are means ± SD. 
 
 
 
 
 
 
Gene Fold change  
(Cyp27b1 null vs. 
Cyp27b1+/-littermates) 
P value Fold change  
(WT vs. Cyp27b1+/-
littermates) 
P value  
Cyp27b1 0.007 ± 0.006 vs. 
1.000 ± 0.277 
P < 0.05 1.681 ± 0.307 vs. 
 1.000 ± 0.424 
P <0.05 
Cyp24a1 0.523 ± 0.476 vs.  
1.000 ± 1.081 
P=NS 1.353 ± 0.476 vs.  
1.000 ± 0.613 
P=NS 
S100g 0.958 ± 0.358 vs.  
1.000 ± 0.261 
P=NS 0.967 ± 0.305 vs. 
1.000 ± 0.241 
P=NS 
Pmca1 0.837 ± 0.079 vs.  
1.000 ± 0.122 
P < 0.05  0.873 ± 0.174 vs.  
1.000 ± 0.076 
P=NS 
NaPi2a 0.861 ± 0.679 vs.  
1.000 ± 0.442 
P=NS 1.404 ± 0.620 vs.  
1.000 ± 0.428 
P=NS 
NaPi2b 1.151 ± 0.637 vs.  
1.000 ± 0.317 
P=NS 0.693 ± 0.275 vs. 
1.000 ± 0.327 
P=NS 
NaPi2c 0.841 ± 0.731 vs.  
1.000 ± 0.724 
P=NS 0.927 ± 0.276 vs. 
1.0007 vs. 0.276 
P=NS 
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Figure 27: Expression of Trpv6 mRNA in Cyp27b1 null versus Cyp27b1+/- placentas 
(A) and in Cyp27b1 null versus WT placentas (B). Values are means ± SD and the 
number of observations are indicated in parentheses. 
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Figure 28: Expression of Pthrp in Cyp27b1 null versus Cyp27b1+/- placentas (A) and 
in Cyp27b1 null versus WT placentas. Values are means ± SD and the number of 
observations are indicated in parentheses. 
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3.7 Expression of renal genes as assessed by qPCR  
 
Expression of genes related to calcium and phosphorus transport were examined in 
kidneys of Cyp27b1 null fetuses and their Cyp27b1+/- littermates, as well as in kidneys of 
WT fetuses and respective Cyp27b1+/-  littermates (Table 2).  
 
Cyp27b1 null fetal kidneys showed the expected absent expression of Cyp27b1. In a 
comparison of WT kidneys versus their Cyp27b1+/-littermates, there appeared to be a 
trend towards higher Cyp27b1 expression in the WT kidneys; however, this was not 
statistically significant (Table 2). 
 
Between Cyp27b1 null fetuses and Cyp27b1+/- littermates there were no differences in 
expression of Cyp24a1, calcium transporter Pmca1 or Napi2a, Napi2b and Napi2c.  
 
We did observe a significant decrease in renal expression of S100G, which encodes for 
Calbindin-D9k, between null fetuses and Cyp27b1
+/- littermates (0.304±0.11 vs. 
1.00±0.63). This data is consistent with the role of Calbindin-D9k in calcium transport in 
the kidney. 
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Table 2: Expression of genes related to calcium and phosphorus transport within the kidney 
of Cyp27b1 null fetuses versus their Cyp27b1+/- siblings and WT fetuses versus their Cyp27b1+/- 
siblings. Values are means ± SD. 
 
 
 
Gene Fold Change 
(Cyp27b1 null vs. 
Cyp27b1+/- littermates) 
P Value Fold Change  
(WT vs. Cyp27b1+/- 
littermates) 
P Value  
Cyp27b1 
 
Absent Expression N/A 1.408 ± 0.364 vs. 
1.000 ± 0.239 
P = NS 
Cyp24a1 1.252 ± 1.232 vs. 
1.000 ± 0.576 
P = NS 1.221 ± 0.563 vs. 
1.000 ± 0.614 
P = NS 
Pmcab1 1.038 ± 0.142 vs. 
1.000 ± 0.265 
P = NS 0.987 ± 0.158 vs. 
1.000 ± 0.212 
P = NS 
S100g 0.304 ± 0.114 vs. 
1.000 ± 0.626 
P < 0.05 0.823 ± 0.110 vs. 
1.000 ± 0.341 
P = NS 
Napi2a 0.847 ± 0.436 vs.  
1.000 ± 0.386 
P = NS 0.865 ± 0.214 vs. 
1.000 ± 0.276 
P = NS 
Napi2b 1.059 ± 0.251 vs. 
1.000 ± 0.329 
P = NS 0.959 ± 0.246 vs.  
1.000 ± 0.082 
P = NS 
Napi2c 0.866 ± 0.271 vs. 
1.000 ± 0.436 
P = NS 0.830 ± 0.218 vs.  
1.000 ± 0.527 
P = NS 
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IV. DISCUSSION 
 
The role of calcitriol, the active, hormonal form of vitamin D, is critically important in the 
regulation of calcium and bone metabolism in both the child and the adult.23,24,159 Without 
calcitriol’s actions to stimulate passive and active absorption of calcium and phosphorus, 
serum calcium and phosphorus are low, PTH levels are increased, while bone grows 
abnormally and is undermineralized.  However, the role of calcitriol in fetal bone and 
mineral homeostasis is less clear.  
 
Prior study of fetuses with disrupted vitamin D physiology, including vitamin D deficient 
rodents, Cyp27b1 null pigs, and Vdr null fetuses, have suggested that calcitriol is not 
required to regulate fetal bone and mineral metabolism. In particular, Vdr null fetuses, 
which have the genetic inability to respond to calcitriol, have normal serum calcium, 
phosphorus, PTH, amniotic mineral content, skeletal morphology, and skeletal mineral 
content in comparison to WT siblings.131,137 Furthermore, calcitriol must not be required 
to stimulate placental calcium transport because Vdr null fetuses were found to have an 
increased rate of transport, and upregulated placental expression of two factors that are 
required for placental calcium transport: PTHrP and the calcium channel TRPV6. These 
findings were consistent with the vitamin D deficiency models, and suggested that 
calcitriol is not required to regulate fetal calcium homeostasis, skeletal development or 
mineralization, and placental mineral transfer. However, Vdr null fetal mice were found 
to have high circulating levels of calcitriol.131,137 Therefore, we hypothesized first that 
calcitriol is not required for bone and mineral homeostasis. Secondly, we hypothesized 
that the upregulation of placental function in the Vdr null fetuses may be due to calcitriol 
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having physiological effects to reduce placental calcium transfer, such that when calcitriol 
has no receptor to signal through, calcium transport increases due to loss of calcitriol’s 
normal effects as a “brake” on the forward flow.  However, this hypothesis is unable to 
explain why models of vitamin D deficiency do not show increased placental calcium 
transport.169   Alternatively, we considered that since Vdr null fetuses have higher than 
normal concentrations of calcitriol, it is conceivable that such high levels of calcitriol act 
through non-classical receptors, such as Pdia3 (discussed below) to upregulate placental 
calcium transport despite the absence of VDR. Such an action might not be physiological 
but only brought about with high concentrations of calcitriol, and this would explain why 
both Vdr null fetal mice and fetal sheep treated with pharmacological doses of calcitriol 
had increased placental calcium transport.  
 
In order to test these hypotheses, we studied Cyp27b1 null fetuses, who cannot synthesize 
calcitriol. If our first hypothesis held true, Cyp27b1 null fetuses would have normal serum 
minerals, hormones, bone mineral and bone morphology in comparison to their 
Cyp27b1+/- littermates and related WT fetuses. If our second hypothesis held true then 
placental function would be upregulated in Cyp27b1 null fetuses. However, if the third 
hypothesis held true, placental function would be normal, or possibly downregulated in 
the Cyp27b1 null fetuses. 
 
In brief, our main findings were that Cyp27b1 null fetuses have normal placental calcium 
transport and expression of genes related to placental calcium transport, Trpv6 and Pthrp, 
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which supports that the third hypothesis is confirmed by the data. I will now discuss these 
results in more detail.  
 
4.1 Maternal calcitriol can rescue Cyp27b1 null fetuses  
 
Previous research from our lab (unpublished) set out to examine Cyp27b1 null fetuses  
using a traditional breeding scheme, by mating Cyp27b1+/- males and females together to 
generate mixed sex litters of null, heterozygous and WT offspring.160 Cyp27b1 null 
fetuses derived from these crosses were determined to have normal serum calcium, 
phosphorus, PTH, amniotic mineral content and skeletal morphology in comparison to 
their WT siblings. However, this approach was confounded by the unexpected finding of 
detectable amounts of calcitriol in the null fetuses, due to passage of calcitriol across the 
placenta from the Cyp27b1+/- mothers. Most previously published data had suggested that 
25OHD crosses the placenta, whereas vitamin D and calcitriol do not.93 However, there is 
one study that supports the passage of calcitriol across the placenta.162 Therefore, while 
this breeding approach did not result in a true calcitriol-depleted fetus, it confirmed the 
presence of significant passage of calcitriol across the placenta from the maternal 
circulation. Moreover, it suggests that infants lacking Cyp27b1 have calcitriol at birth due 
to “rescue” from their heterozygous mothers. The current project compared fetuses from 
Cyp27b1 null mothers to those of WT mothers. In this way Cyp27b1 null fetuses were 
truly calcitriol deficient.  
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4.1.1 Cyp27b1 null fetuses of Cyp27b1 null mothers are devoid of calcitriol, although 
Cyp27b1 null mothers gain calcitriol from their Cyp27b1+/- fetuses 
Calcitriol was undetectable in Cyp27b1 null fetuses, and equivalent to the values 
observed in non-pregnant Cyp27b1 null mice. Thus, Cyp27b1 null fetuses generated in 
this manner truly lacked calcitriol. On the other hand, the calcitriol level of Cyp27b1 null 
pregnant mothers appeared to increase compared to the non-pregnant value. This suggests 
that there was reverse flow of calcitriol across the placenta from heterozygous placentas 
or fetuses to the mother, thereby partly rescuing the mother. We have reported this 
previously in our studies of maternal physiology of Cyp27b1 null females across 
pregnancy and lactation.159 This phenomenon has also been shown in studies of anephric 
rats administered radio-labelled 25OHD. In these studies, some calcitriol was evident in 
pregnant dams while non-pregnant rats had no calcitriol.163,164 This suggests that the 
placenta can contribute some calcitriol to the maternal circulation in rodent models. The 
same cannot be said for humans, as demonstrated through a vitamin D sufficient,  
anephric pregnant woman who continued to have low calcitriol levels despite her baby’s 
normal placenta.165  
 
However, although the Cyp27b1 null mothers had some calcitriol, this was evidently not 
enough to rescue their Cyp27b1 null fetuses, since their calcitriol level was undetectable. 
Of course, the possibility that what was undetectable by ELISA might have been 
detectable by the standard methodology of liquid chromatography tandem mass 
spectrometry (LC-MS/MS) cannot be fully eliminated. Regardless, it is clear that 
Cyp27b1 null fetuses had either no calcitriol or very low levels of it, and were largely 
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unaffected by its absence. 
 
4.2 Calcitriol is not required to regulate fetal bone and mineral homeostasis 
 
A number of experiments were conducted in order to assess calcitriol’s role in the 
regulation of fetal bone and mineral homeostasis. In depth study of Cyp27b1 null fetuses 
borne of Cyp27b1 null mothers demonstrated no differences in serum calcium, 
phosphorus, PTH, ash weight and skeletal mineral content, tibial morphology, placental 
gene expression or placental calcium transport. These results support our hypothesis that 
calcitriol is not required to regulate fetal bone and mineral homeostasis. If calcitriol were 
required, we would have expected to see decreased serum calcium and phosphorus, an 
increase in PTH, as well as rachitic changes in the tibias.  
 
Prior animal data are consistent with these findings. Study of vitamin D deficiency, loss 
of VDR, and loss of Cyp27b1, have all indicated that calcitriol is not required to maintain 
serum calcium and phosphorus, PTH, ash weight, skeletal mineral content, skeletal 
morphology and transport of calcium and phosphorus across the placenta.93 There are two 
reasons that may explain why calcitriol is not required in the regulation of fetal bone and 
mineral metabolism. Firstly, it is clear that calcitriol’s main role in both the child and the 
adult is to stimulate intestinal calcium absorption,21 as deletion of VDR from only the 
intestinal cells causes a rachitic phenotype in mice, while Vdr null mice can be  
genetically rescued (phenotypically normal) by selectively expressing VDR only within 
intestinal cells.73,74 However, within the fetal system, the intestinal mineral absorption 
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pathway is a minor circuit as the placenta is the dominant organ of mineral transport from 
mother to fetus.121,147,148 Secondly, calcitriol is not required for mineral transport across 
the placenta to occur, 131,139 since the absence of calcitriol in Cyp27b1 null mice did not 
reduce or increase placental calcium transport. 
 
4.3 Differences in loss of Cyp27b1 and VDR on placental function  
 
Although study of vitamin D deficient, Vdr null and Cyp27b1 null fetuses have shown 
clear and consistent evidence that calcitriol does not play a role in fetal bone and mineral 
homeostasis, there are notable differences between Vdr null and Cyp27b1 null placentas.  
 
Prior study from our lab of Vdr null fetuses, which have high levels of circulating 
calcitriol, indicated a non-significant increase in placental calcium transport in both Vdr 
null fetuses born of Vdr+/- mothers and those born of Vdr null mothers in comparison to 
WT littermates, when studied in isolation. However, when these data sets were pooled, a 
significant increase in placental calcium transport in the Vdr null fetuses was revealed. 
Vdr null fetuses also displayed an increased expression of placental Pthrp, known to 
stimulate placental calcium transport, and Trpv6 mRNA131 These findings were later 
confirmed by an independent group using an alternate Vdr null model, which also 
displayed significant increases in placental calcium transport, and placental expression of 
calcium transporter Trpv6 mRNA in Vdr null fetuses in comparison to their Vdr+/- 
littermates.137  
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In contrast, in the current study, Cyp27b1 null fetuses, which cannot synthesize calcitriol, 
had normal transport of calcium across the placenta, as well as normal placental 
expression of both Trpv6 and Pthrp mRNA, as compared to both their Cyp27b1+/- 
littermates and related WT fetuses.  
 
Taken together, these comparative results imply that the high levels of circulating 
calcitriol in the Vdr null fetuses are able to act on an alternate receptor to stimulate 
placental calcium transport. This may explain why some prior animal studies found an 
increase in placental calcium transport in animals treated with pharmacological doses of 
calcitriol.93 However, at normal physiological concentrations, calcitriol may have no 
significant effect on placental calcium transport or the placental expression of Pthrp and 
Trpv6, as loss of Cyp27b1 does not alter these placental parameters. This is consistent 
with vitamin D deficiency models which exhibit normal levels of placental calcium 
transport. 139,140 Overall, this may imply that the “pharmacological” effects of very high 
calcitriol concentrations in Vdr null fetuses, and with pharmacological administration of 
calcitriol in normal fetuses, may not be relevant to normal physiology. However, these 
findings may still be relevant to human pregnancies in which the baby has HVDRR, 
related to loss of VDR signaling.  
 
4.5 Renal response to calcitriol  
 
Renal gene expression studies indicated that loss of fetal Cyp27b1 had no effect on 
expression of calcium transporter Ca2+- ATPase or the sodium phosphate transporters 
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Napi2a, Napi2b and Napi2c. However, there was an observed decrease in calcium 
transporter S100G, which encodes for calcium binding protein Calbindin-D9k, in Cyp27b1 
null fetuses in comparison to their Cyp27b1+/- littermates. This result confirms that the 
kidneys are responsive to fetal calcitriol levels. The decrease in renal expression of 
S100G in the Cyp27b1 null fetuses is consistent with calcitriol’s ability to stimulate 
Calbindin-D9k to transport calcium within the kidney cells. The absence of an effect due 
to fetal calcitriol on renal excretion of calcium and phosphorus (as measured by amniotic 
fluid mineral content), adds to previous evidence that the renal-amniotic fluid pathway 
plays a minimal role in fetal mineral homeostasis. These data contrast with placental 
expression of S100G, which was unchanged in Cyp27b1 null fetuses in comparison to 
their Cyp27b1+/- littermates. The lack of change in placental S100G is consistent with 
prior studies in vitamin D deficiency models,139,140 and suggests that S100G is not 
regulated by calcitriol in the placenta.  
 
 
4.6 Maternal calcitriol directly or indirectly regulates fetal mineral metabolism 
 
Although the presented evidence is that fetal calcitriol does not regulate fetal bone and 
mineral homeostasis, maternal loss of Cyp27b1, and therefore calcitriol, had modest 
effects on the fetuses that were independent of fetal genotype. Whether these were direct 
or indirect effects is not clear. Lack of maternal Cyp27b1 led to significantly increased 
concentration of calcitriol’s precursor 25OHD3 and the vitamin D metabolite 24,25-
dihydroxyvitamin D in the fetal serum. It is likely that lack of maternal metabolism of 
25OHD3 into calcitriol in the Cyp27b1 null mothers led to higher values crossing the 
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placenta where it accumulates to reach a higher concentration of 25OHD3. Consequently, 
the higher amount of 25OHD3 may have led to more 24,25-dihydroxyvitamin D3 simply 
due to more substrate being present.  Fetuses borne of Cyp27b1 null mothers also had 
increased calcium content and decreased phosphorus content in amniotic fluid (an index 
of fetal kidney function), and significantly reduced serum FGF23. PTH was non-
significantly decreased in fetuses of the Cyp27b1 null mothers, as compared to those 
borne of WT mothers. In each of these cases, both Cyp27b1 null and Cyp27b1+/- fetuses 
borne of Cyp27b1 null mothers were indistinguishable, but different from both Cyp27b1+/- 
and WT fetuses borne of WT dams. This suggests that these differences are solely due to 
loss of maternal calcitriol, and not due to fetal genotype. As there are differences due to 
maternal genotype across multiple parameters, it is convincing that maternal genotype has 
a real effect on fetal parameters that are independent of fetal genotype. It is currently 
unknown whether these differences lead to any persistent changes in the neonates or older 
pups.  
 
These results indicate that maternal calcitriol plays a direct or indirect role in regulating 
fetal FGF23 and fetal renal excretion of calcium and phosphorus. Also, by implication, 
fetal PTH, since the non-significantly lower PTH levels in fetuses of null dams might 
explain the findings of increased calcium and reduced phosphorus in amniotic fluid.  It is 
likely that maternal calcitriol has a direct effect on these parameters of fetal bone and 
mineral homeostasis, as preliminary work in our lab which led to my project showed 
detectable levels of calcitriol in Cyp27b1 null fetuses borne of Cyp27b1+/- mothers.160 
This is supported by a prior study of human placenta and an in vitro perfusion system to 
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determine that calcitriol can cross the placenta.162 Furthermore, it is known that 25OHD 
readily crosses the placenta, so it is logical that calcitriol would also be able to cross the 
placenta as it only differs by one hydroxyl group. 93 
 
4.7 Rescue Diet 
 
Supplementation with calcium, phosphorus and lactose has been shown to prevent the 
rachitic phenotype and normalize fertility in Cyp27b1 null and Vdr null post-weaning and 
adult mice.155,166 Similar findings have also been demonstrated in human studies, in which 
the lactose content of breast milk has been shown to increase calcium absorption in 
babies.166  The ability of the rescue diet to prevent the rachitic phenotype is through 
passive intestinal calcium absorption and is consistent with the important roles of both 
calcitriol and VDR on intestinal calcium and phosphorus absorption through upregulation 
of calcium transporters.26,141,168 This may help explain why children and adults with 
vitamin D deficiency display a rachitic phenotype but fetuses do not. The placenta is the 
dominant supplier of mineral in the fetal circulation and the intestines play a much lesser 
role. Neither calcitriol nor VDR are required for placental mineral transport.131 
Thus, for the purpose of this study, and to ensure that fertility was optimized, Cyp27b1 
null and WT mothers were kept on an enriched rescue diet (2% calcium, 1.25% 
phosphorus and 20% lactose) in order to support fertility.  
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4.8 Study Limitations 
4.8.1 Comparison of fetuses borne of Cyp27b1 null versus WT mothers 
As previously mentioned, prior study in our lab determined that Cyp27b1 null fetuses 
borne of Cyp27b1+/- mothers have detectable levels of calcitriol due to significant 
transplacental passage of calcitriol from the mother. Thus, the Cyp27b1 null fetuses 
generated for this study came from matings of Cyp27b1 null females with Cyp27b1+/- 
males. While this mating scheme was successful in generating true calcitriol-depleted 
fetuses, it doesn’t allow for null and WT fetuses to be compared within the same litter. 
However, this may be considered a strength in that WT and Cyp27b1 null mothers are 
close relatives from the same colony and we were able to control for any changes that 
may be displayed in the fetuses due to maternal differences by comparing Cyp27b1+/- 
fetuses borne of Cyp27b1 null and WT mothers.  This allowed us to determine that the 
significant differences in serum FGF23, amniotic fluid calcium and amniotic fluid 
phosphorus content, between Cyp27b1 null and WT fetuses were due to loss of maternal 
calcitriol rather than loss of fetal calcitriol.  It is possible to generate WT and null fetuses 
within the same uterus; however, it would require transferring blastocysts in culture to 
pseudopregnant dams, which is well-beyond the scope of this project.  
4.8.2 Use of the rescue diet  
Use of the rescue diet which is high in calcium, phosphorus and lactose, may confound 
our findings by providing extra mineral to the Cyp27b1 null mothers.  However, the use 
of the rescue diet is necessary in order to allow for normal fertility, and thereby provide 
readily available pregnancies to study Cyp27b1 null fetuses during the time frame of a 
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Master’s project. Moreover, use of the rescue diet mimics the human condition, because 
pregnant women lacking CYP27B1 are treated with high doses of calcium,93 if they are 
unable to afford calcitriol treatment which is quite expensive. To control for any 
differences due to rescue diet, both WT and Cyp27b1 null mice were kept on the rescue 
diet from birth. 
4.8.3 Calcitriol assay  
There is a possibility that there were circulating levels of calcitriol in the Cyp27b1 null 
fetuses that were not detected by the ELISA assay. However, Dr. Glenville Jones, a 
expert in the field in vitamin D measurement, suggests that the ELISA assay is more 
sensitive than the standard methodology of LC-MS/MS (personal correspondence). 
Therefore, calcitriol levels would have also been undetectable using this LC-MS/MS.  
4.8.4 The ability of the mouse model to reflect the human condition 
The Cyp27b1 mouse model is used to study PDDR, characterized by loss of function of 
the CYP27B1gene in humans. The Cyp27b1 knockout mouse model mirrors PDDR quite 
well. Much like humans with PDDR, who appear normal at birth and present with 
symptoms of rickets at 1-2 years of age, Cyp27b1 null mice also appear normal at birth 
and present with hypocalcemia, hypophosphatemia, secondary hyperparathyroidism and 
rickets after weaning. 81  One notable difference between the Cyp27b1 mouse model and 
the human condition is that calcitriol is able to pass through the placenta from the fetus to 
the maternal circulation in the mouse model, whereas the human placenta does not allow 
for this passage of calcitriol from the fetus to the mother. 165 
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4.9 Relevance to Human Health 
 
The Cyp27b1 mouse model is very consistent with the human condition of PDDR. 
Moreover, such studies are not possible on human fetuses, so we must rely on the animal 
models to inform us on the human condition. Although data from these studies suggest 
that calcitriol is not required for fetal bone and mineral homeostasis, they do not imply 
that vitamin D insufficiency should be ignored during human pregnancy. Instead, they 
reassure us that human fetuses born of vitamin D deficient mothers, as well as mothers 
with PDDR or HVDRR, should be normal, as previous clinical studies have also 
suggested. 169 In addition, we know that the neonate needs vitamin D shortly after birth 
(as hypocalcemia can begin as early as 48 hours after birth in fetuses born of vitamin D 
deficient mothers), and so it is best that the newborn start off with sufficient levels, even 
if unnecessary during fetal life. 
 
4.10 Future work  
 
4.10.1 Identification of calcitriol’s alternate putative receptor 
Contrasting data of placental function between Vdr null fetuses (which have high levels 
of circulating calcitriol) and Cyp27b1 null fetuses (which cannot synthesize calcitriol) 
suggest that calcitriol may act on an alternate receptor, that has not yet been identified, in 
order to upregulate placenta calcium transport and related gene expression in the Vdr null 
fetuses. A future direction for this project includes identification of this alternate putative 
receptor. RNA-sequencing of placental tissue may help to identify the differentially 
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regulated genes that allow calcitriol to upregulate placental function in the Vdr null 
fetuses. One possible known receptor to study is Pdia3, which is associated with rapid 
membrane-initiated signaling by calcitriol.170 In order to study this, we would ideally 
generate a double knockout of Vdr/Pdia3. However, since previous study of Pdia3 null 
mice have shown that Pdia3 null fetuses die before ED 12,170 it would be best to study 
mice that are both Vdr null and have a conditional (floxed) knockout of Pdia3 within their 
placentas.  An alternative approach to this would be to cross Vdr null mice with Pdia3 
heterozygotes. Pdia3 heterozygotes have a distinctive bone phenotype which suggests that 
this may be a possible solution.170 
4.10.2 Confirmation of calcitriol’s role in upregulation of placental calcium 
transport in Vdr null fetuses 
Since these studies found that loss of calcitriol, through loss of Cyp27b1, did not 
appreciably disturb normal placental function, it appears that the high levels of circulating 
calcitriol in Vdr null fetuses are able to work on an alternate receptor in order to 
upregulate placental calcium transport. To confirm this, Cyp27b1/Vdr double knockout 
mice could be studied.171 In this way, if Cyp27b1/Vdr double knockout fetuses have 
normal placental calcium transport, we would know for sure that it is the high levels of 
calcitriol in the Vdr null fetuses that upregulate placental calcium transport in these mice. 
Alternatively, this could be studied using mice that are both Vdr null and vitamin D 
deficient.  
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4.10.3 Postnatal study of Cyp27b1 null pups 
To date, there are no studies that look at the role of calcitriol in the neonate. It would be 
interesting to study Cyp27b1 null pups borne of Cyp27b1 null mothers after weaning to 
determine if the effects due to loss of maternal calcitriol that were evident in utero lead to 
any progressive alterations in mineral or bone physiology in the offspring before or after 
weaning.  
 
4.10.4 Study of Cyp27b1 null mothers mated to Cyp27b1 null males 
It would be ideal to conduct an experiment to compare Cyp27b1 null mothers mated to 
Cyp27b1 null males with Cyp27b1 null mothers mated to Cyp27b1+/- males, to be certain 
that the calcitriol in the mother in the current study isn’t rescuing the null fetuses. But this 
is beyond the scope of the current project, but may pose an interesting follow-up study.  
 
4.11 Summary  
 
Transplacental passage of calcitriol from Cyp27b1+/- mothers to their fetuses can provide 
near-normal concentrations of calcitriol in fetuses lacking Cyp27b1. However, when 
Cyp27b1 null fetuses are borne of Cyp27b1 null mothers, and thus are truly calcitriol 
depleted, they display normal serum minerals, PTH, FGF23, renal excretion of calcium 
and phosphorus into the amniotic fluid, placental calcium transport, as well as placental 
and renal expression of genes related to calcium and phosphorus transport. Of 
importance, the normal placental calcium transport and placental expression of Trpv6 and 
Pthrp mRNA contrasts that of Vdr null fetuses, which have increased placental calcium 
transport, and expression of Trpv6 and Pthrp mRNA in comparison to their Vdr+/- and 
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WT counterparts.131,137 These results suggest that high or pharmacological levels of 
calcitriol may act on an alternate receptor to stimulate placental calcium transport and 
expression of Trpv6 and Pthrp. Such actions of calcitriol are not necessarily 
physiological, since WT fetuses normally have low levels of calcitriol. Furthermore, 
fetuses borne of Cyp27b1 null mothers differ in serum 25OHD, 24,25-dihydroxyvitamin 
D, FGF23, and amniotic fluid calcium and phosphorus, and possibly PTH, in comparison 
to fetuses borne of WT mothers. These findings suggest that maternal calcitriol has 
effects on fetal mineral homeostasis that are independent of the fetal genotype. Whether 
they are direct or indirect effects of maternal calcitriol will be determined in future 
studies. 
 
4.12 Conclusion  
 
My research hypothesis stated that, firstly, calcitriol is not required for bone and mineral 
homeostasis. Secondly, we hypothesized that the upregulation of placental function in the 
Vdr null fetuses may be due to calcitriol having physiological effects to reduce placental 
calcium transfer, such that when calcitriol has no receptor to signal through, calcium 
transport increases due to loss of calcitriol’s normal effects as a “brake” on the forward 
flow.  Or alternatively, we hypothesized that since Vdr null fetuses have higher than 
normal concentrations of calcitriol, it is conceivable that such high levels of calcitriol act 
through non-classical receptors to upregulate placental calcium transport despite the 
absence of VDR. My studies of Cyp27b1 null fetuses agree with our first hypothesis that 
calcitriol is not required for bone and mineral homeostasis. My studies also agree with the 
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alternate version of the second hypothesis, that calcitriol can act through non –classical 
receptors to upregulate placental calcium transport despite absence of VDR.  
To conclude, fetal-sourced calcitriol is not required to regulate fetal bone and mineral 
homeostasis. However, when the current findings are contrasted with those of Vdr null 
fetuses, which have abnormally high concentrations of circulating calcitriol, it is apparent 
that calcitriol may be able to act on an alternate receptor, that has not yet been identified, 
in order to explain the upregulation of placental function that occurs in Vdr null fetuses 
and with pharmacological treatment with calcitriol, as opposed to the lack of upregulation 
in placental calcium transport and gene expression that occurs in fetuses that lack vitamin 
D or calcitriol. Loss of maternal calcitriol caused modest effects on the fetal phenotype 
that were independent of fetal calcitriol levels, but, these effects were relatively masked 
by the ability of the placenta and fetus to maintain bone and mineral homeostasis without 
fetal calcitriol.  Whether these modest effects of loss of maternal calcitriol on fetal bone 
and mineral homeostasis have any long-term effects on neonatal, child, or adult mineral 
and bone metabolism, are beyond the scope of this MSc thesis and remain the subject of 
future investigations. 
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